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                                                 ABSTRACT 
Gastric  carcinoma  is  the  second  common  cause  of  cancer  related  
worldwide deaths.  The HER-2/neu is the Human epidermal growth factor 
receptor-2 and it is a gene localized on chromosome 17q21 that encodes a growth 
factor receptor like molecule with tyrosine kinase activity and has a structure 
similar to that of epidermal growth factor receptor. Its expression has been detected 
in several human cancers and is believed to be associated with poor prognosis, 
aggressive biological behavior and metastatic potential. The present study is to 
evaluate the presence of HER-2/neu in gastric  cancers  of  all histological  types. 
IHC is an excellent technique to detect HER-2/neu expression in Gastric  
carcinoma. Their  prevalence  in  gastric  cancer  ranges  from   9-38% in most  
studies. This study included 50 cases of gastric  carcinoma and these were 
subjected to immunohistochemical staining for HER-2/neu oncoprotein. Out of  50 
cases , only  8  cases of  Gastric  adenocarcinoma (16%)  were found to be positive 
for HER-2/oncoprotein. In this  study  Her2 neu  expression  is  more  in  
Oesophageal  gastric  junctional tumours & corpus  location  of  stomach tumours 
(35.3%) compared to Pylorus-Antral  tumours. And  also  we  observed  Her2 neu  
expression in  patients  with  signet  ring  cell carcinoma  (40%)  compared  to  
Non signet  ring  cell  carcinoma. 
KEYWORDS: Gastric Carcinoma, IHC, HER-2/neu 
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INTRODUCTION 
Every  year  3 million new cases  of  gastrointestinal  tract  cancers  
are  reported  world   wide
1
.  Gastric  carcinoma  is the  second  common  
cause  of  cancer  related  deaths  and  it  was  responsible  for  more  than  
738,000 cancer  deaths  in  2008
2 
.  Gastric  cancers  are  the  second  most  
common  cancers  in  women  and  fourth  most  common  in  men
3,4
.  
Gastric  cancer  is  associated with  a  higher  number  rate  of  cancer  
related  deaths, more  than  other  common  malignancies  like  colon  and  
breast
5
.Predominant  gastric  malignancies (95%) are  epithelial  in  origin
6
.  
The  frequency  of  the  gastric  cancer  varies  according  to  the  geographic  
locations,  diet  and  lifestyle  habits.  Japan  and  South Korea  and  China  
have  the  highest incidence rates, while  low  incidence  rates  are  reported 
in  north America and  Africa
3,7,8,9
. 
Gastric  cancer  is  very  rare  below  the  age  of  30  years.  The  age  related  
incidence  rises  sharply  and  peaks  in  the  age  group  of  60-80  years
10
.  
In India,  gastric  cancers  are  common  in  the  age  group  of  45  to  55  
years  in  North India  and  35  to  55  years  in  South  India. Males  are  
more  prone  to  gastric  cancer  than  females
 3
. In  India,  the  frequency  of  
gastric  cancer  is  higher  in  the  south  and  north  eastern  states. 
The state  Mizoram  reported  an  age  adjusted  incidence  rate  of  
50.6  and  23.3  for  male  and  female  respectively
11
.  There  is  a  constant  
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decline  in  incidence  and  mortality  rates  of  gastric  carcinoma  in  
industrialised  countries. 
Surgical  removal  of  the  primary  tumour  is  curative  in  stage  I  
cancers,  but  for  more  advanced  stage  gastric  cancers,  surgery  combined 
with  postoperative  chemotherapy  and  or  radiation  is  used.  But  the  
survival  rates  are  still  low
12
. Advanced  gastric  cancers are  strongly 
associated  with  poor outcome  with  a  median  survival  of  patients  with  
metastasis  at 7 to  10  months  from  initial  diagnosis 
13
.  
TNM  stage  is  a  dependable  prognostic  tool  in  gastric carcinoma  
patients, but patients with similar TNM-stages been  observed  to  have  
different  clinical  outcomes. Even  with  aggressive  chemotherapy,  
recurrences  are  common  in  these  patients,  even  in  early  stage  of  
disease  and  hence  the   average  five  year  survival  remains  between  30  
to  50%14 .  Hence  the  need  of  new  and  non traditional methods  of  
prognostication  of   gastric  cancers.  The  present  regimens  of  
chemotherapy  give  unsatisfying  results,   hence  a  need  for  a therapy  for  
a  therapy  regimen  that  is  tailored  to  the individual patient  based  on  the  
molecular pathways associated with tumour cell growth, proliferation, 
invasion,  and  metastasis and  that  which  is  specific to tumour-related 
molecular targets. One   such example  is  the  drug  targeting  the  human 
epidermal growth factor  receptor2 (HER2) in patients with breast cancer. 
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The prognostic significance and  prevalence  of HER2/neu in patients with 
gastric carcinoma  is less established than in breast cancer. Their  prevalence  
in  gastric  cancer  ranges  from   9-38% in most studies
15
, although values as 
low as 2.5% to as high as 91% have been reported
16
.  Some  studies  has  
identified  HER2/neu  as  a  poor  prognostic  factor  for  survival,  some  
have  reported  the  same  as  a  positive  prognostic  factor and  others  have  
failed  to establish  the  relationship
15-18
.  Hence  the  reports  of  the  
correlation  of  HER2/neu  and  Gastric  cancers  is  conflicting  and  hence   
needs  more  study. 
 
The  prognostic  significance  of  HER2/neu  in  gastric  carcinoma  is  
still  under  study.  Current best practice for assessing HER2 in gastric 
cancer involves  immunohistochemistry (IHC) followed by molecular 
analysis of HER2/neu gene amplification, by fluorescent in  situ  
hybridization (FISH)
19
. This methodology was not  widely  accepted  until  
2010.In  this study,  the  expression  of  HER-2/neu  in  gastric  cancer  is  
studied  by  immunohistochemistry.  The  correlation  between  HER-2/neu  
expression  and  the  clinicopathological  parameters  of  the  patients  are 
analysed.
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AIMS  &OBJECTIVES 
1. To Assess  the  expression  of  HER2/neu  in  gastric  cancers  of  all  
histological  types.  
2. To  describe  the  relationship  between   HER2/neu  expression  in  
gastric  adenocarcinoma  and  the  Clinicopathological  data  of  these  
patients.  
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REVIEW OF LITERATURE 
EMBRYOLOGY 
 
The stomach develops as a fusiform dilation of the foregut at the 4mm stage 
in week
21
. The primordium soon enlarges and broadens ventro-dorsally. Its 
position and appearance changes  as a result of the different rates in the 
growth, as well as changes in position of the surrounding organs.  The 
positional changes are explained by the antero-posterior axial rotation of the 
stomach. The stomach carries out a 90 clockwise rotation around the 
longitudinal axis, causing its right side to face posteriorly and its left side 
anteriorly
20
.  Antero-posterior  axis rotation displaces  the cephalic portion 
towards  left and  slight  downward and  the pyloric part of the stomach 
towards  right and upward, resulting in the future duodenum coming to be 
retroperitoneal.(Figure1) 
                    The dorsal part of the stomach grows faster than the ventral part 
which results in formation of the greater and lesser curvatures of the 
stomach.  Stomach  is  attached  to  the  posterior  body  wall  by  dorsal  
mesogastrium  in  this  stage. Longitudinal axial  rotation pulls the dorsal 
mesogastrium towards  left and helps  in  the   formation  of  lesser  sac. 
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Figure 1. Embryological development of  stomach 
 
As the embryo lengthens, the  distal   part of the septum transversum 
becomes the mesogastrium  of  the  stomach,  which   attaches the  
duodenum  and  stomach   to   the ventral wall of the abdominal cavity.  
Then   stomach  assumes its final position, in  which  greater curvature faces 
downward, and the lesser curvature faces  to  the  right  and  upward . 
ANATOMY
 
The  stomach is divided  grossly  into four  regions:  cardia, fundus, 
body (corpus) and  pylorus. It extends  as  a  J  shaped  loop   from the  distal  
end  of  oesophagus  at  the  level  of  11
th 
thoracic  vertebrae,  to just right of 
the  1
st
  lumbar  vertebra  inferiorly, where it connects to the duodenum. The 
stomach   begins from  the   GEJ,  which  is  the  proximal  part of the  
gastric  folds  and   ends at the pylorus, where the  circular  smooth muscle  
thickens  to form the pyloric sphincter.  The  concavity  towards   right, 
  
7 
 
 
 
forms  superomedial  margin  is termed  as  lesser curvature and  the 
convexity of  the  left, outer curve forms  inferomedial  margin,  which 
considered to  be greater curvature.  The  angle  at  which  the  pylorus  
narrows  before  the  gastroduodenal  junction  termed  as incisuraangularis. 
               Topographically, the stomach is divided into  following  five 
regions  (Figure 2). 
1. The cardia is a narrowest (0.1 to 0.4 cm in length)  and  
macroscopically  indistinct  portion of the stomach  which  is  located 
immediately distal to the GEJ. 
2. The fundus  is  known as dome  of  the  stomach   which  is  just  
beneath  the  diaphragm  and  extends superolateral to the 
oesophagogastric  junction. 
3. The body  of  the  stomach   represents  the largest  portion  of  the  
stomach  and  it  comprises the  proximal  2/3
rd
of the remainder.     
 
 
 
 
 
 
 
Figure 2.Topography  of  the  stomach 
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4. The  part  of  stomach  which  is  distal  to  the incisura is  termed  as  
pylorus antrum.  It  is distinguished  from the  proximal  duodenum by 
the pyloric sphincter.  
5. The  pylorus  has  no  easily  visualised  landmarks, but  is  easily  
palpated  as  a  ring  of  muscle  which  separates  the  stomach  and  
duodenum.  
The gastric wall consists of  mucosa, submucosa,  muscularispropria, 
and serosa. The interior surface of the gastric  mucosa  shows  coarse  rugae,  
which  flattens  when  the  stomach  gets  distended.  Rugae  or folds  are  
more  prominent  in  the  proximal  stomach. 
Blood supply and lymphatic supply: 
The blood supply of the stomach originates from the celiac axis, 
hepatic artery, and splenic artery. The  stomach  is  richly  vascularised  
organ,  with  contributions  from  five  major  sources (Figure 3).  
1. The  right  gastric  artery , a  branch  of  proper  hepatic  or common  
hepatic  artery,  which  anastomoses  with  left  gastric  artery   and   
supplies  the  distal  portion  of  lesser  curvature.  
2. The  left  gastric  artery,  a  smallest  branch  of  celiac  axis,  which  
supplies  the  cephalad  portion  of  the  lesser  curvature. 
3. Right  gastroepiploic  artery  supplies  antrum  and  lower  part  of  
body,  which  originates  from  gatroduodenal  artery.    
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4. Left  gastroepiploic artery supplies  upper  corpus  which  originates  
from  splenic  artery.   
5. A series  of short  gastric  arteries  from  splenic  artery, which  
supplies  proximal  stomach. 
The  right  and  left  gastric  veins  drains  into  the  portal  vein,  left  
gastroepiploic  vein  into  splenic  vein  and  right  gastro  epiploic  vein  into  
superior  mesenteric vein.   
 
 
 
 
 
 
Figure 3.  Branches of celiac trunk 
 
Lymphatic  drainage: 
Lymphatic  drainage  pathways  run  in  close  proximity  to   the  
arterial  supply (Figure 4)
22
.The lymph vessels drain into four major areas, 
according to the following scheme: 
1. Upper  lesser curvature: left gastric nodes  and  para  cardinal  nodes  
via  superior  gastric group. 
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2. Pylorus and  caudal  portion  of   lesser curvature: right supra 
pancreatic  nodes  via  suprapyloric  group. 
3. Cephalic  portion of the greater curvature: splenic  and  left 
gastroepiploic  nodes  via   pancreaticosplenic group. 
4. Caudal portion of greater curvature: right gastroepiploic nodes  via 
Subpyloric  group. 
 
 
 
 
 
 
Figure  4  Lymphatic drainage of the stomach. 
 
Eventhough  these  lymph  nodes  drains  different  region  of  the  
stomach,  it  remains  widely  accepted  that  gastric  carcinoma  may  
metastasize  to  any  of  the  nodal group  irrespective  of  their  location. 
Innervation: 
The  extreme  innervation  of  the  stomach  is  both  sympathetic 
through  celiac  plexus and  parasympathetic  through  the  vagus.  The  
anterior  (left)  vagus  gives  off  the  hepatic  branch  to  liver  and  continues  
as  the  anterior  nerve  of  latarjet  along  the  lesser  curvature (Figure 5)
23
. 
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The  right  vagus  gives  a  branch  off  to  celiac  plexus  and  tending  to  
supply  posterior  surface  of  the  stomach.  In contrast,  sympathetic  nerve  
supplies  arise  from  D6-D10  travelling  through  the  splanchnic  nerve  to  
the  celiac  ganglion  and  spreading  thence  to  stomach.
24
 
 
 
 
 
 
 
Figure 5.Vagal  innervation  of  stomach 
Histology: 
The organization of the gastric mucosa is similar in all regions  of  the  
stomach
25
.  Gastric  mucosa  consists  of  columnar  epithelia,  which 
invaginated from  the  surface  form  the  gastric  pits (foveolae). Gastric  
glands  extends  from  the  pits  into  the  mucosa,  which vary  in the  
structure and function in the three regions.  
The lengths of the  glands  and   pits  also  exhibit  variability in the three 
regions  of  the  stomach. The cardiac portion of the stomach extends a short 
distance from the junction with  the  oesophagus  to  the  fundus, it usually 
extends  for  5–30mm  distal  to  cardio-oesophageal junction.
25
It is 
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characterized by  equal length of  foveolae and glands  and  it  has  loosely  
packed  mucus-secreting  cells. Surface mucous cells line the  foveolae, 
which project inwardly  from  the  surface  of  the  organ  which   secretes  a 
protective coat of mucus that prevents the mucosa from being digested by 
the acidic environment of the lumen. 
The  fundus  part  of  the  stomach  which  lies above an imaginary, 
horizontal line through the  oesophageal  orifice  and  the body  of  the  
stomach, which is below that line. The fundus and main body of the stomach 
are similar in their histologic structure.  Body  and  fundal  mucosa  consists 
of  tightly  packed  straight  tubular   glands  which  arranged perpendicular  
to the surface (Figure 6),  that synthesise and secrete gastric juice. The 
gastric pits  form  superficial  zone  which  occupies  25%  of  the  total  
thickness  and  each has between one and seven gastric glands opening into 
it. 
 
 
 
 
 
 
Figure 6. Normal body mucosa 
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The  gastric  glands  of  the  body  mucosa  exhibit  four  types  of  
cells. They  are  mucous  neck  cells,  chief or  peptic  cells (zymogenic  
cells), acid  secreting  parietal  or  oxyntic  cells  and  endocrine cells.
25,26
The 
rest of the wall is composed  of the  muscularis mucosae,  submucosa, 
muscularis propria, and serosa, as are the other regions of the stomach. 
Below the muscularis mucosae is the connective tissue of the submucosa. 
Fibroblasts  and  other  cellular  components  of  connective  tissue,  as  well  
as  blood  vessels  and  nerve  fibers  are  found  in  the  submucosa. Beneath  
the submucosa,  the  external  smooth  muscle  layers  are  arranged  in  
indistinct  inner  oblique, middle  circular, and  outer  longitudinal  patterns.
 
Outer longitudinal, inner circular, and innermost oblique layers  are  the  
three  layers  of  the  muscularis externa.  The  serosal  layer  of  the  stomach 
is  continuous with the serosal   lining  of  the  peritoneal  cavity.  Pyloric  
mucosal  zone  occupies  distal  3-4cm  of  the  stomach,  in contrast to the 
simple  straight  glands of the fundus and body, the pyloric glands are coiled  
tubules,  some  of  it  branched  which  occupies  50%  of the  thickness  of  
the pyloric mucosa, and separated by upgrowths of muscularis mucosae 
(Figure 7).  
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Figure 7 Normal Antral mucosa. 
 
The pyloric glands are lined almost exclusively by mucus-secreting 
cells, which are similar to the neck mucous cells of the gastric body and 
fundus. In addition to mucus-secreting cells, pyloric glands also contain cells 
of the diffuse neuroendocrine system that produce the peptide hormone 
gastrin, which promotes acid secretion by the parietal cells. 
PHYSIOLOGY 
The  principle  function  of  the  stomach  is digestion of food and  
absorption  as  it  is  propulsed  through  small  intestine.  The  initial  period  
of  digestion  require several  hours  while  they  undergo  physical  
breakdown  of  the  bolus   of  food  into  a  semisolid  mass  known  as  
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chyme.  The strong muscular action of the stomach mechanically reduces 
food, and the action of enzymes secreted  by the cells of the stomach 
chemically digests proteins. In  the   stomach,  the  food  suffers  significant  
physicochemical  changes  which  as  a  result  of  the  secretor  and  motor  
activity  of  the  stomach. The mechanical activity of the  stomach consists of 
the presence of peristaltic waves, which  helps  in  gastric evacuation, 
contractile activity of the stomach being continuous during both digestive 
and inter digestive periods. The  gastric  glands secretes gastric juice,  which  
made up of 99% water and 1% inorganic substances - hydrochloric acid, 
mainly, and organic substances, mucin and gastric enzymes: pepsin, rennin, 
gelatinases, lipase. The endocrine secretion of the stomach is represented by 
the secretion of gastrin, somatostatin, histamine, or leptin. The  functions  
and  the  cells  lining  the  glands  vary  according  to  the  region  of  the  
stomach (Table 1) 
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Table 1   Gastric  cell  types,  location, and  function 
Cells Location Function 
Parietal 
 
Body 
Acid secretion  and intrinsic 
factor 
Mucus Body, Antrum Mucus 
Chief Body Pepsin 
Surface epithelial Diffuse Mucus. Bicarbonate 
Enterochromaffin- like Body Histamine 
G Antrum Gastrin 
D Body, Antrum Somatostatin 
Gastric mucosal 
interneurons 
Body, Antrum Gastrin-releasing peptide 
Enteric neurons Diffuse Calcitonin gene- related peptide 
Endocrine Body Ghrelin 
 
EPIDEMIOLOGY: 
The  incidence  of  the  gastric  carcinoma  varies  according  to  their  
geographical  location.  The  incidence  of  gastric  cancer  in  India  is  less  
compared  to  worldwide  incidence. The age – adjusted rate (AAR)  of  
gastric  cancer  among  urban  registries  in  India  is  3.0 -13.2  compared  to 
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worldwide  AAR  4.1- 95.5.
27-30  
The  age – adjusted  incidence  rate  of  
stomach  cancer  in  males  varies  widely  among  registries,  highest  being  
11.2/ 100,000  in Chennai  compared  to  1.6/ 100,000  in  Bhopal
31
.  In  
India  highest  incidence  rates  are  found  in south  and  northeast  regions. 
In  2010,  nationally  representative  survey  found  556,400  number  of  
deaths  occur   due to cancer,  in  which  gastric  cancer  shows  12.6%  
mortality  rate and  considered  to  be  the second most  widely  known  
cancer.
32
 Gastric  cancer  is  unusual  below  the  age  of  forty  years  and  
climbs  thereafter  and  attain  peak  in  the  seventh  decade  of  life.
33
 
In  India   male  to  female  ratio of  the  incidence  was  2.3:1. the  
median  age  for  men  was  58  years  and  for  women   57  years.
34
  Five-
year  survival  for  gastric  cancer  is  nearly  20%. Survival  rates  are  higher  
in  countries  which  have  effective  screening  programs  that  lead  to  early  
detection  and  where  distal  cancer  predominates.
35
 
PATHOBIOLOGY OF GASTRIC CARCINOMA: 
The pathogenesis of gastric carcinoma involves multiple risk  factors.  
More  than 60%  of  gastric cancer cases have been  contributed to H.pylori 
infection. In  addition  to  infections,  other  conditions  such  as diet, 
cigarette  smoking, male  gender,  genetic factors,  nitrates, chemicals, 
socioeconomic  status   and  other  pathological conditions  in stomach  can  
also   contribute to  tumoriogenesis. Gastric carcinogenesis   is  a  multi-step  
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process,  with the following sequential stages:  progression  from  the  
normal  gastric  mucosa   through  chronic  gastritis  which  gradually  results  
in  atrophy, then  intestinal metaplasia and dysplasia.
36 
RISK FACTORS ASSOCIATED WITH GASTRIC CARCINOMA: 
A.Helicobacter pylori infection 
Warren  and marshall  discovered  the H.pylori organism 1982
37
.  It  is 
a  Gram- negative  bacteria found in the  normal  stomach  mucosa  that  can  
be  remain  alive  and proliferate in the  stomach, and  it  has been  
acknowledged  as an  significant  risk factor for gastric carcinoma
38,39
.  
Higher  prevalence  is  much  more  common  in  developing countries  when  
compared  with  developed countries . H.pylori  is  usually  acquired  during  
childhood  and  most  frequently  run  in  families  with  low  socio  
economic  status
40
.  It  has  been  classified  as  group  I  carcinogen  by  
WHO.  Approximately   50% of world population is infected by H.pylori
41
  
and it  is associated with increased  risk of developing gastric 
cancer
42
.NotAll  the  infected  individuals  prone  to  develop  pathological  
lesions. (Figure8). Thus, the factors determining  gastric cancer development 
remain largely unknown. 
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Figure 8. clinco pathological outcome  associated with H.Pylori infection 
H.pylori  infection  is  associated  with  both diffuse and intestinal  
type gastric cancer. It  shows  a  high  degree  of  genetic heterogeneity, so 
several  virulence   factors of  the  bacterium  also  plays a role,  which  
establish the  outcome of  the  infection. CagA-positive  strain produces  
higher  level  of  IL 8,  it  often  elicits  intense  inflammatory  reaction  
which  are  associated  with  raised  risk  of  gastric  carcinoma. Compared  
with CagA-negative  strain,  CagA-positive bacteria induces severe  
inflammation  and have been associated with greater risk for peptic ulcer 
disease, as well as preneoplastic and neoplastic lesions
43
. Smoking  act  as  
an  additive  factor  which  significantly  raises the  risk of gastric carcinoma  
whiich  is  associated  with CagA positive H. pylori infection 
44
.  H. pylori 
infection  is  very  unusual  with adenocarcinoma of the gastric cardia
45
. 
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Other  important  bacterial  virulence  factors  are  VacA,  adhesins.  The  
ultimate  mechanism  by  which  H. pylori  induces  stomach  cancer  
remains  unknown. Eradication of Helicobactor  infection seems to be  
decrease  the incidence of gastric carcinoma
46
 
B .Dietary and lifestyle factors 
Diets  rich in salty  foods  such  as   salted  meat,  dried  fish,  smoked  
fish  and  pickled  foods  which  favours  intra luminal  formation  of  
genotoxic  agents  and  it  has  been  found  to  be  related  with  development  
of  gastric  carcinoma.  Food  rich  in  citrus  fruits  and  vitamin C, 
vegetables are  inversely  associated  with  risk  of  developing  gastric  
adenocarcinoma
47,48 
A high  salt  intake  act  as  an irritant  to the  stomach  mucosa  which  
elicit  mucosal  damage  and increases  epithelial  cell  proliferation. 
Numerous  studies  have  found  smoking  has  been  associated  with  gastric  
carcinoma
 49,50
. High  alcohol consumption  also can  also  act  as  a  risk  
factor  for gastric cancer
51
, but this has not been the case in all studies 
50
.Increased  risk  was  also  observed  among  the  tobacco  chewers
52
. 
Hyperglycaemia  add significant  risk  for  gastric cancer, especially among 
H. pylori positive cases
53
.  Capsaicin  may also act  as  a  risk  factor  for  
gastric  carcinoma
54
. Adequate intake of vitamin C is associated with lower 
gastric cancer risk
55
.  
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A study in Colombia showed that after 6 years of dietary supplementation 
with vitamin C and beta-carotene, partial regression  of gastric precancerous 
lesions was observed
56
 . 
Low socioeconomic  status and  its  correlates  increased  the  risk  of  
developing  gastric cancer
49,50
. 
C. Family history and genetic conditions 
Family history 
First- degree  relatives of  the  affected  person  are  nearly  three  
times  higher  risk  of  developing  gastric  carcinoma  compared  with  
general  population
57
.  CagA  positive  H.pylori  infection  associated  with  
family  history  of  gastric  cancer    and  it  has  16 – fold  risk  of  
developing  non cardia  gastric  cancer
58
. 
Genetic conditions 
Most  gastric  cancers  are  sporadic  in  nature. But 8-10% of gastric 
cancer  cases  are  associated  with  inherited  genetic components 
59
. Table-2 
summarises common  gastric  sporadic  neoplasms  and  their  genetic 
alterations. 
Table 2   sporadic  neoplasm and their genetic alterations 
Tumour Genes Involved Common Genetic Alterations 
Gastric 
Carcinoma 
P53, CDH1,c-erbB-2, cmet,  
MLH1,MSH2,MSH6,PMS2, MSH3,Loss 
or gain of 3p,4,5q,6q,9p,17p 
Pointmutation, duplication, 
deletions, Insertions or Gain 
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Hereditary diffuse gastric carcinoma  
Familial diffuse gastric cancer  usually  common  in  younger  age  
group
60
. It is an autosomal dominant inheritable  condition.75%  of  gastric  
cancer  tumours  associated  with  germ line mutations of  E-cadherin 
(CDH1) gene  which  forms  truncated  proteins
61
.The  age  of  onset and 
diagnosis is  in-between 14 to69 years. These hereditary diffuse gastric 
carcinomas  usually  manifests as diffuse or poorly differentiated carcinomas 
with an  extensive  infiltrative growth pattern, often  contains signet-ring 
cells
62
. In  Addition, methylation of the CDH1 gene promoter  isalso  results  
in  hereditary diffuse gastric carcinoma
63
 . Patients  with inherited genetic 
disorders, such as inherited  BRCA1 and BRCA2  genes  and  HNPCC  may  
also  associate  with  increased  risk  of  developing gastriccarcinoma
64 
Table-3 summarises  common  Inherited  Genetic  syndrome and  their  
genetic alterations. 
D  Gastric surgery 
The  increased  risk  of  developing  gastric  cancer  in  the  gastric  stump  of  
patients  who  undergone  previous  gastric  surgery
65
,particularly bilrothII  
gastrectomy  operation which increases bile reflux. The  occurrence  of  bile  
reflux  in turn  promotes  gastric  carcinogenesis.
66 
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Table 3   Inherited  Genetic  syndrome  &their  genetic alterations 
Syndrome Gene Involved Genetic Alterations 
Juvenile  polyposis 
syndrome 
SMAD4,  BMPR1A, 
PTEN 
Deletion, insertion, 
missense & nonsense 
mutation 
Peutz-Jeghers 
syndrome 
STK11/LKB1 Deletion, insertion, 
missense, splicing 
mutations 
Hereditary diffuse 
gastric cancer 
CDH1 Frame shift & missense 
mutations 
Familial 
adenomatous 
polyposis 
APC Frame shift & missense & 
nonsense mutations, 
deletions, duplication 
Lynch Syndrome 
(HNPPC) 
MLH1, MSH2, MSH6, 
PMS2, MSH3 
Deletion & Duplication 
 
E  Pernicious anemia 
In  1950  it  was  recognised  as  a  important  risk  factor  for  gastric  
carcinoma
67
. And its considered to  be  a  risk factor for non-cardia gastric 
cancer.
68
 
F  Polyp 
Gastric polyps may be sporadic or associated with  polyposis 
syndromes. E.g. FAP, PJS, juvenile polyposis, and cowden’s disease
67
. 
Adenomatous  polyp  is  well  known  recognised  entity  which  may  
progress  into  malignancy.  The  risk (2-1.5%) of  developing  gastric  
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cancer  varies  according  to  the  type ,size  of  polyp   and  grade  of  
dysplasia
68
. 
G  Epstein- barr virus 
It is  a  well  known  causative  agent for mononucleosis and  also  
which  has  been  related  to burkitt’s lymphoma, nasopharyngeal carcinoma 
and gastric cancer
69 
H.  Occupations 
A few  number  of  occupations  has  been  recognised  as  a  risk  
factor  for  gastric  carcinoma, which  includes  mining, fishing, timbre and  
farming  as  well  as  found  in  asbestos  and  rubber  workers. 
Other factors  which  are  found  to  be   associate with gastric cancer 
includes  hypertrophic gastropathy, Metenier’s disease, low socioeconomic 
status, chronic atrophic gastritis and obesity
33,70
 
CLINICAL MANIFESTATIONS 
Gastric adenocarcinoma  lacks  specific  symptoms  early  in  the  
course  of  disease,  often  ignore  early   vague  epigastric  discomfort  and  
indigestion  which  are  often  mistake  for  gastritis. The  epigastric  
discomfort  similar  to  pain  caused  by  benign  ulcer.  Typically  this  pain  
is  constant,  non  radiating  and  cannot  relieved  by  food  ingestion. 
Locally  advanced  disease  or  metastatic  disease  produces  physical  signs  
during  late  in  the  course  of  the  disease. Very  large  advanced  tumours  
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often  obstructs  the  lumen,  which  impairs distention  of  the  stomach and  
produces  symptoms  like  nausea, vomiting, fullness  of  stomach
33
. 
Clinically   significant  GI bleeding  is  rare,  but  as  many  as  15%  of 
patients may develop hematemesis  and  anemia.  Patients may present with 
apalpable abdominal mass, cachexia, enlarged  palpable  supraclavicular  
nodes (Virchow’s) or periumbilical (Sister Mary Joseph’s)
33,71
 lymph node, 
peritoneal  seeding  palpable  by  rectal examination (Blummer’s shelf)
3
,  or 
a palpable ovarian mass (Krukenberg’stumor)  and  may  develop 
hepatomegaly  and  ascites  and  edema  secondary  to  metastasis. 
MACROSCOPIC CLASSIFICATION OF GASTRIC CANCER 
(i) Early  gastric  cancer 
Early  gastric  cancer  is  classified  macroscopically  into  three  types  
based  upon  the  gross  appearance  of  the  lesion  found  on the  mucosal  
surface (Figure 9). The endoscopic or macroscopic classification of gastric 
carcinoma  recognised  by Japanese Gastric Cancer Association.  Now  it  
has  been  widely  accepted,  which  was  approved  in   2002  at  an  
international workshop  in Paris
57
. 
TypeI -  Protruding type -  These  are  polypoidal  tumour  more  than  
2.5mm  in  size,  which  projects  above  the  level  of  mucosa.  
Type II – Superficial  type– This  type  subclassified  into three groups: 
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Type IIa - Elevated  lesion , equal  or  less   than  2.5mm  in  size,  the  
thickness  of  the  mucosa  is  twice  the  thickness  of  normal  mucosa. 
Type IIb-  Flat  lesion,  less  than  5mm  in  size.  Very  difficult  to  
diagnose  through  endoscopically. 
Type IIc-  Depressed  lesion. The surface of  the  tumour  is slightly 
depressed than  the  surrounding  normal  mucosa 
Type III – Excavated type – This  type  shows  prominent  depression  with 
ulceration. 
 
 
 
 
 
 
 
 
 
 
 
Figure 9: Gross classification of early gastric cancer 
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II 
III 
IV 
Approximately  80%  of  early  gastric  cancer  are   Type  II  lesions 
while  diagnosed,  and  type  IIc  lesion  is  most  commonest   macroscopic  
type. 
(ii)  Advanced  gastric  cancer(AGC) 
Borrmann  classification  is  the  widely  used  macroscopic  
classification  for  AGC. (Figure 10) 
Type I – Polypoid-  these  are  well circumscribed  polypoidal  tumours 
Type II –Fungating-  fungating  tumours  with  central  ulceration  or  
infiltration. 
Type III – Ulcerative –ulcerated  tumours  with   infiltrative  or  heaped up 
margins. 
Type IV – Diffusely  infiltrative  tumours. 
 
 
 
 
   
 
 
 
Figure 10. Borrmann classification of gross types of advanced gastric cancer 
I 
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According  to  borrmann  classification,  type  II  tumours  are  the  
most  commonest  type  in  advanced  stage,  which  are frequently  seen  in  
lesser  curvature  of  the  antrum. Type I  &  Type  III  tumours  are  usually  
found  in  greater  curvature  of  the  stomach.  Infiltrative cancers  can  
spread superficially  in  the  mucosa  and  submucosa  via  lymphatics   
producing  plaque-like  lesions. It  is  usually  accompanied  by  thickness  of  
the  entire  stomach  wall  producing  the  so-called  linitisplastica  or  leather 
bottle stomach. 
CLASSIFICATIONS OF GASTRIC CARCINOMA: 
Based  on  the  histological  appearance of the tumour,  several  
classification systems  has  been  proposed. 
Ming  classification 
It  classifies gastric  adenocarcinoma  into  expanding  and  infiltrative  
types
72
(Figure 11a,11b ). The  expanding  type  comprises  67% of  gastric  
adenocarcinoma. It  corresponds  to  the  Lauren’s  intestinal type  of  
carcinoma.  It  is  characterised  by  aggregates  of   cells  which  is 
circumscribed and well delineated  and  surrounding  tissue  compressed  
aside. 
 
  
 
 
 
Figure 11a  Expanding  type  of  gastric carcinoma.
The  infiltrative  type  of
Lauren’s  diffuse - type  of  carcinoma. It  is  characterised  by  wide  
infiltration  of  isolated,  individual  tumour  cells.
have  better  prognosis than  infiltrative  type  of  adeno
Figure 11b   .Infiltrative  type  of  gastric  carcinoma
Goseki  classification 
Goseki  proposed   a  classification  based on the  amount  of  mucus  
production  and  degree of tubular  differentiation. This  system  provides  
29 
  gastric  carcinoma  corresponds  to    
 Expanding  type  tumours  
carcinoma.
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more  accurate prognosis  for advanced  gastric  cancer  when it  used  with  
the  tumour-node  metastasis (TNM) system. 
Carneiro classification  
Carneiro et  al  proposed a much  more  simpler system in which the 
tumours are  divided  into  glandular,  isolated  cell  carcinomas, solid variety 
and a mixed type  that  consists  of  a  mixture  of  glandular  and  isolated  
cell types
73
. 
Histologic classifications 
Lauren’s
74
  has  proposed  two  tier  classification system  based  on  
their  gland  forming  tendencies. The  diffuse  and  intestinal  type  which  
corresponds  to  the  undifferentiated  and  differentiated types  respectively, 
according  to  Nakamura   classification  system.
75 
Mixed  carcinoma  consists  of  almost  equal  amount  of  diffuse  and  
intestinal  components.  Indeterminate  category  consists  of  too 
undifferentiated  carcinomas  that  cannot  fit  into  either  category
74
.
 
Approximately  the  frequencies  are  32% -diffuse  type,  54%- intestinal, 
15%  of  indeterminate  type.  
Intestinal carcinomas 
These  tumours  usually  have  glandular  pattern  and  they  are  
thought  to  arise  from  metaplastic  epithelium  (Figure 12). The  degree  of  
differentiation  inversely  correlates  with  size  of  tumour. In  well  
  
 
 
 
differentiated  tumours, most  of  the  cells  are  mucin  secreting  or  
columnar  in  nature.  Occasionally  it  shows  complete  intestinal  
metaplasia. The  amount  of  mucin  pro
stroma  of  the  tumour  is  heavily  infiltrated  by  histiocytes  or  
neutrophils. 
 
 
 
 
 
Figure 12. Lauren’s  & WHO  intestinal  type  of  gastric  adenocarcinoma
Diffuse carcinomas 
It  usually  occurs  in  
adenocarcinomas  are  classically  known  as  linitis  plastic  and  currently  
known  as  signet  ring  carcinoma.  Sections  from  the  gastric  wall  shows  
submucosal  fibrosis  and  hypertrophic  muscular  wall  which  
evidenced  by  comb  like  appearance.  Histologically  it  shows  poorly  
cohesive  malignant  cells  diffusely  infiltrating the gastric wall  with  
extensive  fibrosis  and  inflammation.  The  cells  usually grows  
individually  and  glandular  fo
cytoplasmic mucin  secretion  resulting  in  signet  ring  cell  appearance.
31 
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Figure 13  diffuse  type  of  gastric carcinoma
The  intestinal  type  of  gastric  adenocarcinoma  has  been  
considered  to  originate  from  the  background  of  intestinal  metaplasia  
and  diffuse  type  of  gastric  adenocarcinoma  originated  from  normal  
gastric  mucosa. Both  tumours  follows  different  genetic  pathways  in  
tumorigenesis.
77,78
However,   phenotypic cel
extensively  expressed  in  gastric adenocarcinomas, regardless of   their  
microscopic type 
79-82
.
 
Phenotypic classification
Phenotypic  classification  of  gastric  adenocarcinoma   based  on  the  
type  of  mucin  secretion,  which  can  be  detected  by  using  gastric  and  
intestinal  markers  histochemically  or  immunohistochemically. Mucins  are  
glycosylated  glycoproteins  secreted  by  gastro  intestinal  epithelial  
cells.
83-85
The  secretary  product  of  
an  acid  muco substance  which  can  be  easily  detected  by  mayer
mucicarmine  stains.  The  mucin  secreted  by  the  diffuse  type  of  gastric  
32 
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intestinal  type  of   gastric carcinoma  is  
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adenocarcinoma  are  usually  present  within  the  cytoplasm of  the  signet  
ring  cell  carcinoma.    Mucins  are  exclusively  referred  as  MUC   
indicated  with  number,  which  exhibiting  the  order  in  which  the  mucin  
was  derived.  There  is existence  of  correlation  between  the  type  of  
mucin secretion and  tumour  location.  At  the  immune  histochemical  level  
the  main  mucin  types  expressed  are  MUC5AC  for  diffuse  carcinoma,  
MUC1  for  intestinal  type  carcinoma,  MUC2  for  the  mucinous  
carcinoma  and   MUC5B  for  unclassified  type  of  gastric  
adenocarcinoma.  
Secretory  mucins  and  transmembrane  mucins  are  the  two  types  
of   mucins  described.  Secretary  mucins  which  act  as  a  defense  barriers  
for  surface  of  gatric  epithelium.   Transmembrane  type of  mucins  which  
act  as  a  ligands  in  cell  signalling  pathways
85
. Mucin  plays  a  important  
role  in  normal  physiological  functions  and  also  in  pathological  changes  
in  tumour  metastasis.  
There  are  two  types  of  mucus  secreting  cells  in  gastric  mucosa.  
They  are  glandular  mucous  cells  and  surface  mucous  cells
83
. The  
expression  of  mucin  in  gastric  adenocarcinoma  is heterogeneous.  It   
consist  of   gastric  phenotypic  markers  like  MUC5AC, MUC1,  MUC6  
and intestinal  phenotypic  marker  MUC2
84,85
.  According  to  this  
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phenotypic  markers  expression,   gastric  adenocarcinomas  are  classified 
into  following  four  differentiated  types
79
. 
 G type  tumours - It  shows  positivity  for  gastric  phenotypic  
marker,  not  for  intestinal  marker.   
 I type  tumours- This  tumour    expresses  only  intestinal  phenotypic  
marker,  never  express  gastric  marker.   
 GI (combined) type - It  shows  positive  results  for  both  intestinal  
and  gastric  markers.  
 UC (unclassified type)-  It  does not  show   positivity  for  any  of  the  
phenotypic  marker. 
World Health Organization classification 
In  2010  World  health  organization  recognises  four  important  
histologic types  of  gastric adenocarcinoma. They  are  tubular  carcinoma, 
papillary adenocarcinoma,  mucinous  carcinoma and  poorly cohesive  
carcinoma  which  includes  signet  cell carcinoma.  Several   other rare  
variants  are  included  under  WHO  classification 
41
(Table 4).  The  
classification  is  based  on  the  principal   or  dominant  histological  
pattern,  which  may  be  associated  with  other  types  of  the  carcinoma . 
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WHO (2010) Classification  of  gastric  carcinoma
68
 (Table4) 
Papillary adenocarcinoma 
Tubular adenocarcinoma 
Mucinous adenocarcinoma 
Signet-ring cell carcinoma 
And other poorly cohesive carcinoma 
Mixed carcinoma  
Adenosquamous carcinoma 
Squamous cell carcinoma 
Hepatoid adenocarcinoma 
Carcinoma with lymphoid stroma 
Choriocarcinoma 
Carcinosarcoma 
Parietal cell carcinoma 
Malignant rhabdoid tumour 
Mucoepidermoid carcinoma 
Paneth cell carcinoma 
Undifferentiated carcinoma 
Mixed adeno-neuroendocrine carcinoma 
 
         Continued.... 
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Continued.... 
Endodermal sinus tumour 
Embryonal carcinoma 
Pure gastric yolk sac tumour 
Oncocytic adenocarcinoma 
 
Tubular adenocarcinomas 
Tubular  adenocarcinoma  is  the  commonest  histological  entity  of  
EGC.  It  usually  forms  fungating  or  polypoidal  mass  and  histological  
picture  shows  predominantly  composed  of  neoplastic tubules  with  
varying  diameter  often  shows  irregular  branching  and anastomosis  
which  embedded   in  the  fibrous stroma  and  conspicuous  desmoplasia 
(Figure 14 )Individual tumour cells are columnar, cuboidal, or  flattened by 
intraluminal mucin.  The  degree  of  atypia varies from high  to  low  
grade
87,88
.  
 
 
 
 
 
 
Figure14. Neoplastic, branched tubules in tubular adenocarcinoma 
  
 
 
 
A poorly differentiated type is  otherwise  known  as  solid  
carcinoma.  Another  variant  known  as  onc
recognised .A  poorly  differentiated  variant  is sometimes called solid 
carcinoma. 
Papillary adenocarcinomas
It  is  an  another  important  histological  variant  found  in  early  
gastric  cancer. Usually  common  in  older  individuals,  and  frequently  
shows  liver  and nodal  metastasis.  
demarcated  tumours with po
which  are  lined  by  cuboidal cells  with  central  fibrovascular  cores  and  
admixed  with  acute  and  chronic  inflammatory  cells (Figure15 ). Some of  
the  tumour  shows  papillo tubular differenti
with   micro papillary architecture.  It  may  be  associated  with  cellular  
atypia ,  nuclear  pleomorphism  with  varying  mitotic  index.
 
 
 
 
 
 
Figure 15. Papillary projections lined by neoplastic cells.
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Mucinous adenocarcinomas
It  is  characterized  by  prominent glandular  structure  with  large amounts 
of extracellular  mucin  in  atleast  50% of the tumour  cells.  It  represents 10 
%  the  of  gastric  cancer. It  has  two  important  growth  patterns.
Formation  of   glands   which  are  lined by   mucus
cells (well  differentiated  type).  
 Tumour  cell   arranged  as  a  disaggregated   irregular  ribbons  
which appears  to  be  float  in the  lakes of mucin (poorly 
differentiated type) 
 Mucin  also be present  in  inter
be  associate  with  scattered signet
unreliable  if  the  tumours  contains  only  few  cells. 
 
 
 
 
Figure 16  Clusters of 
Signet-ring cell carcinomas
                 By  definition  it  comprises  isolated  single  cells or  tight  cluster  
of  cells  with  an  eccentrically  compressed  and  displaced  nuclei  having  
38 
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intra-cytoplasmic  mucin  which  accounts  for  more  than 50% of the 
tumour (Figure 17). These tumours are more common in younger patients 
and in the distal stomach.
 
 
Figure 17 prominent intracellular mucin with eccentrically pushed nucleus
Five  morphological  pattern  of  tumour  cells  have  been  described. 
1. Nuclei  which  push against cell membranes and  forms classic signet  
ring  cell appearance  due  to  clear  and  expanded  cytoplasm. It  
usually  contain  acid  mucin   which  stains  for 
pH  of 2.5 
2. some  of  the  signet  cells  resemble  signet  ring  cell  which  shows  
centrally  placed  nuclei  with  little   mitosis. 
3. signet  cell contains  neutral  mucin  instead  of acid  mucin  with  
deeply  eosinophilic  cytoplasm  and  prominent  distinct  cytoplasmic  
granules.                 
4. signet  cells  which  is  small  in  size  with  little mucin
39 
 
 
 
 
 
 
 Alcian blue at the  
 
 
 
 
 
  
40 
 
 
 
5. anaplastic cells with  or  without  mucin 
These  signet cell types  were  mingled  with  each  other  and  
constitutes  varying  tumour  proportions.  It  may  also form  lacy  delicate  
glandular  pattern.  Signet cell carcinomas are usually infiltrative  in  nature  
with  prominent  desmoplasia. It  has  great  tendency  to  invade  duodenum  
through  the sub mucosal and  sub  serosal lymphatic  channels,  special  
attention  is  needed  to  those  routes  when  frozen  sections were  requested  
to  evaluate  marginal  status. 
Special stains which  includes  PAS,  alcian  blue, mucicarmine  or  
cytokeratin  immunostaining  are  required  to  identify the  sparsely  
distributed  malignant  cells  in  the  stroma.  Cytokeratin  immunostains   
which  is  superior  than  mucin  stain  to  detect  neoplastic  cells.   
Several other  conditions  can   mimic signet-ring cell carcinoma  
which includes signet-ring lymphoma, xanthomas, laminapropria 
muciphages. Benign  pseudo-signet ring cell is  the  important  differential  
diagnosis  for  malignant  signet  ring  cells. Even though  this  pseudo-signet 
ring cells  demonstrates  cytological atypia  and  mitoses  it  doesn’t  show 
invasion. Reticulin  stain  can  highlight the  pseudo-signet ring cells  which 
is  limited to  basement membrane  and  the  acinar architecture  is  usually  
intact
89
.  
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Micropapillary  carcinoma (MPC) 
Micropapillary  carcinoma  is  a  newly  diagnosed aggressive  rare  
histologic  variant  characterized  by  tiny  papillary clusters of malignant  
cells  which  are  surrounded  by  clear  spaces  with   indistinct  
fibrovascular  core(Figure18).  These   micro papillary features  are  usually  
prominent in advancing  edge of  tumour, with  high  incidence  of  nodal  
metastasis  via  endolymphatic  tumour emboli. The  prognosis  of  the  
micropapillary carcinoma,  not  significantly different  from  conventional  
gastric  carcinoma
 107
. Conservative  treatment   not  advised  for  micro  
papillary  carcinoma  because  of  higher  incidence  of  lymphatic  
invasion
109 
 
  
 
 
 
 
Figure 18  Micro papillary carcinoma lined by a space without lining epithelium. 
 
Other variants 
World  Health  Organisation  also  recognised  other  rare  histologic 
variants, which  are  described  below. 
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Medullary carcinoma 
Gastric carcinoma with lymphoid stroma is  also  known  as   
medullary carcinoma.  It is  one  of  the  uncommon variant  with  less  
aggressive  clinical  course.  It  usually occurs in the  antral/ body  of  the  
stomach. Males  are  more  prone  to  this  type  of  carcinoma. 
Histological  picture  shows  well  demarcated  tumour  composed of 
polygonal tumour cells  which  arranged  in  irregular nests or sheets with a 
prominent  stromal  lymphoid infiltrate  without  desmoplasia (Figure 19a).  
  
  
 
 
 
 
Figure 19a medullary carcinoma with 
lymphoid stroma 
 
 
     Figure 19b Epstein–Barr virus  DNA   
     within tumour cells but not in lymphoid    
     stroma. (In situ hybridization)   
Epstein-Barr virus (EBV) infection  can  be  demonstrated  in  more  
than  80% of  medullary  carcinoma
89,90
(Figure 19b ). This  finding has  
increased  hope for tumour cell targeting, by  using   a proteasome inhibitor  
which induces  EBV kinase  activity  which  in  turn  helps  to   kill  the  
targeted  by other agents
91
.  High microsatellite instability  was  noted  in  
  
43 
 
 
 
another  group  of  GCLS resulting from defective function of   hMLH1 or 
hMSH2
92,93-95
. 
Adenosquamous carcinoma 
It  accounts  for  less  than  1%  of  cases. This lesion  usually  
demonstrates  adeno  and  squamous cell carcinoma  pattern (Figure 20 ) . 
The  collision  tumour  composed  of  two  histologically  distinct  tumour  
pattern. Tumours  often  shows  foci  of   squamous metaplasia  are  known  
as  adenoacanthoma. 
 
Figure 20  Focus  of  squamous cells with mucinous adenocarcinoma 
Squamous cell carcinoma (SCC) 
It  is  a very  unusual in stomach, usually  resembles  SCC  originates  
elsewhere  in  body.  Histological  picture  shows  malignant  squamous  
cells  with  moderate  pleomorphism (Figure 21 ).   
 
 
  
 
 
 
 
 
 
 
 
Figure 21  Gastric  squamous cell carcinoma
Undifferentiated carcinoma
Tumours  lack  differentiation, but  exhibit  cytokeratin expression  are  
included  under  undifferentiated  carcinoma  according  to  WHO.  Further 
analysis by using histochemicalmethods  needed  for  their  separation  into 
other  tumour  types. 
Hepatoid and α-Fetoprotein
Its  another  rare  entity,  there  are  foci  of  neoplastic  tumour cells 
which are large  polygonal  cells  resembles  hepatocellular carcinoma,  
admixed  with the intestinal type  of  gastri
These  are bulky  tumour  with  polypoidal  nature  associated  with  
ulceration,  necrosis and  haemorrhage. A specific  feature  of these  tumours  
are  extensive infiltration of venules, which  causes  high incidence of 
hepatic  metastasis and  worse prognosis than conventional gastric 
carcinoma
98,99,40
.Some  published  studies  has  been  explained  
incidence  of  this variant ranges from 1.3% to 15% of all gastric 
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–producing carcinomas 
c  adenocarcinoma (Figure 22 ) . 
 
the  
  
 
 
 
carcinoma.It  is  unusual  below  the  age of 50. 
for  this  tumour  is  antrum.
when evaluating the primary tumour, but its  very  difficult  when  evaluating  
secondary  liver metastases. 
patients  and  immunohistochemistry   can  demonstrates  within the 
malignant  cell
40
. 
 
 
Figure 22Hepatoid gastric carcinoma showing uniform tumour cells (left)
Choriocarcinoma 
Pure form  of gastric 
shows  combination of  trophoblastic elements within  variably differentiated 
adenocarcinoma (Figure 23). Prominent necrosis and
usually  evidenced . Immunohistochemistry  can  demonstrate
chorionic gonadotropin, and  elevated  HCG  levels  in  the  serum can be 
used as a prognostic  marker. Recently  accepted  pathogenic  explanation  is  
45 
The  most  common  location  
The diagnostic  interpretation  is  very  clear  
Serum  AFPis  usually elevated  in affe
 
 
 
 
 
gastric mucosa (right). 
choriocarcinomas are very rare. Most
 hemorrhage  are  
cted 
 arising in 
 of  the cases 
  human 
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that  these  neoplasm  represents choriocarcinomatous differentiation  of  the  
conventional  adenocarcinoma. 
 
 
 
 
 
Figure 23  Hemorrhagic  neoplasm with  many multinucleated syncytiotrophoblasts 
Carcinosarcoma 
Carcinosarcomas  is  very  rare  in  the  stomach .   Tumours                 
composed     of both adenocarcinomatous and sarcomatous components. 
Sarcomatous elements  comprises uncommitted cells or differentiating  cells  
like chondrosarcoma, leiomyosarcoma,osteosarcoma, rhabdomyosarcoma. 
Small cell carcinoma 
It  is  a  rare  tumour  only  100 cases have been reported  till now.  
These tumours are  usually  diagnosed at  advanced  stage  , so  the prognosis   
of  this  tumour  is  quite  poor.  Most patients usually  die within 1  year of  
diagnosis. The  tumours  resembles  their pulmonary  counterpart,  showing  
neoplastic  cells  arranged  in  sheet like  configuration with   infiltrative 
growth , rosette  formations,  peripheral  palisading of nuclei, inconspicuous 
nucleoli (Figure 24 ) . 
  
 
 
 
 
 
 
 
 
 
Figure 24  shows solid sheets and cords of small “blue” cells
IHC  study  shows 
chromogranin  and  negativity  for  carcino
neuro secretory granules  can  be  demonstrated by  electron microscopy.
Parietal cell carcinoma andoncocytic carcinoma
Parietal cell carcinoma is  an  exceedingly  rare  tumour. These  
neoplasm  has  an  expanding  growth  pattern which  composed of 
polygonal  arranged  in  solid sheets with abundant, granular, eosinophilic 
cytoplasm that   can  be  stained  by phosphotungstic acid
(Figure 25). It has good  prognosis  than  the  conventional  gastric 
adenocarcinomas.Table 5  summarises  uncommon  variants  and  special  
studies  which  used  for  their  diagnosis 
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 embryonic antigen. Characteristic  
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–hematoxylin 
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Figure 25 polygonal  cells  with abundant  granular cytoplasm 
 
Table 5 Pathological  characteristics of rare variants 
Histological Type Histology Special studies 
Hepatoid 
adenocarcinoma 
Large polygonal cells, Bile 
& PAS+ve intracytoplasmic  
eosinophilic globules 
AFP (+) – insitu & 
serum 
Medullary  carcinoma 
with   lymphoid 
serum 
Poorly developed tubular 
structure with prominent 
stroma 
>80% tumours  
associated  with  
EBV infection 
AdenoSquamous 
carcinoma  
>25% of squamous  
component 
- 
Squamous cell 
carcinoma 
Moderately  differentiated  
to  poorly  differentiated 
- 
Gastric small  cell 
carcinoma 
Sheet like  growth with  
rosette like  arrangement 
Chromogranin A and 
NSE +ve, CEA -ve 
 
Gastricmucoepidermoid and Panethcell carcinomas 
Mucoepidermoid carcinoma  shows  mixed  population  of  mucus  
producing  cells and  squamous epithelium.Paneth cell carcinomas is  
  
 
 
 
characterized by neoplasm  with Paneth cell differentiation. 
Immunohistochemistry  reveals characteristic  cytoplasmic granu
showing   positivity  for lysozyme.
Malignant Rhabdoid Tumour
It  accounts  for  nearly 0.1% to 0.2% of all gastric cancers. 
Histological  picture  shows  poorly cohesive neoplastic  polygonal  cells
with  clear  or  acidophilic cytoplasm with  
and  conspicuous nucleoli (Figure 26 ). These rhabdoid
vimentin,  cytokeratin, EMA, focal NSE, but  shows  negativity   for CEA.
Figure 26 Largediscohesive cells  with characteristic eosinophilic cytoplas
Early gastric cancer 
EGC  is  a  carcinoma in  which  neoplastic  tumour  cells  are  limited 
upto mucosa or submucosa, irrespective  of  the  nodal  involvement
(Figure27).  Majority  of  EGC  are  asymptomatic and  usually  occur  in  
elderly  individuals. Rate  of  growth  of  EGC is  usually  slow.  Follow
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large  centrally  placed nuclei  
 
 
m and prominent nucleoli.
les  that 
 
cells  expresses 
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study of dysplastic lesions  usually  demonstrates  the  high  prevalence of 
EGC.  Histological  pictur
Grossly  raised  lesions  with papillary  or nodular  patterns  often  shows  
well or moderately differentiated
shows poorly differentiation . Grossly  ulcerated 
diffuse  or  intestinal   carcinoma. 
 
 
 
 
 
 
Figure 27  Early Gastric cancer  showing  mucosal  involvement
Adenocarcinoma  which  is   limited to  mucosa  has  been  classified  
into 1) small mucosal (less  than 4cm ) 2)  sup
If  they  shows  focal infiltration  into  sub
as  small mucosal SM and superficial SM. 
If  there  is  extensive  sub mucosal  infiltration  than  above
mentioned  variants,  it  is  known
into  PenA and PenB .  PenA
usually   penetrates muscularis  mucosae.
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e  shows  either  pure  form  or  mixed  form.
 intestinal carcinoma. Flat  lesions  usually  
 tumours  consist  of  either  
 
erficial  (more  than  4cm)
-mucosa, it  has  been  classified  
 
  as  penetrating  variant. It
 shows  only  pushing margin,  and  PenB  
100
 
 
 
100
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-
  is  sub  divided  
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Stromal reactions 
These are  the  usual  stromal responses to the  neoplastic  cells. They  
are  desmoplastic stroma,  tumour  lymphocytic infiltrates,  eosinophilic  
infiltration  of  stroma  and   granulomatous  response.  These   
granulomatous reaction  is  evidenced  by  presence  of  single or  confluent 
sarcoid-like granuloma  areas  admixed  with  intense  infiltration  of  
mononuclear cell. 
Grading 
• Well differentiated: Tumour  composed  of  well-formed glands, often 
resembles  metaplastic intestinal epithelium. 
• Moderately differentiated: Tumour  composed   of  glandular  
elements ,  morphologically  intermediate  between  well  to  poorly  
differentiated carcinoma. 
• Poorly differentiated:  Tumour  shows  irregular glandular  elements  
that are difficult  to  recognize ,  which  arranged  in   single cells or  
small  clusters  with  acinar  structures.                   
Tubular  carcinoma may also be graded as low-grade or  high-grade 
(poorly differentiated). 
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SPREAD OF GASTRIC CARCINOMA 
Direct spread 
In  resected  specimens the majority  of  gastric  cancer  tumours  have 
extended  into  sub serosa  and  serosa  and  its  extent  is  greater  in  
infiltrative  tumours. Spread  to  the  adjacent  organs  depends  on the  
location  of  the  primary tumour  growth.   Lower  end  of  oesophagus  can  
be  infiltrated  by  the  gastric  carcinoma  which  arise  from  the  proximal   
portion  of  the  stomach   and  tumours  arise  from  the  distal  part  of  the  
stomach  shows  microscopic  extension  into  the  duodenum
101
. Local  
extension  can  also  occur  in  omentum,  pancreas,  transverse  colon  and  
spleen.  The  diffuse  type  of  carcinoma shows  wider  dissemination  than  
the  intestinal  type  of  carcinoma. Widespread direct spread is  especially 
common with signet ring carcinomas. 
Lymphatic spread 
Lymph node metastases  can  be  found  in 70% of surgical resections and  in 
90% of gastric carcinomas at autopsy
102
. The  nodal  metastasis  of  the  
tumour  is  declining  now,  because  more  lesions  are  diagnosed  at  early  
stage. Depth  of  tumour  invasion  directly  proportional  to the  incidence  
of  the  lymph  node  metastasis,  irrespective  of  the   microscopic  type  of  
primary  tumor
210
. The  tumour  can  metastasise  to  perigastric, peri aortic  
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and  celiac  nodes  via  submucosal  and  mucosal  lymphatic  plexus
104
.  
hepatoduodenal  nodal spread  is  evidenced  in  distal  gastric  tumours
105
. 
Haematogenous spread 
 Vascular  invasion  can  occur  even  in  the  absence  of  nodal  metastasis. 
The  most  common  location  for  distal  metastasis  are  liver  which  is  
followed  by  peritoneum,  lung  and  ovaries. The  diffuse  type  of  gastric  
carcinoma  can  spread  through  peritoneal  seeding  whereas  intestinal  
type  of  gastric  carcinoma usually spread  via  vascular invasion. Intestinal  
type  tumours  may  involves  rare  sites  such  as  spleen, meninges,  kidney  
and  uterus.
106,107 
And gastric  carcinoma  in  younger  age  group  more  prone  for  peritoneal  
metastasis. If  the  liver  metastasis  shows  diffuse pattern  or  peritoneal  
seeding  shows  intestinal  pattern  of  growth ,  the  primary  carcinoma  
often  shows  mixed  pattern. 
Transperitoneal spread 
Secondary metastatic  deposits  from  the  primary  gastric  adenocarcinoma  
are  common  in  peritoneum, omentum  and  mesentry. Metastatic  ovarian  
deposits  from  primary  gastric  adenocarcinoma  known  as  krukenberg’s  
tumour,  which  is  commonly  associated  with  diffuse  type. 
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MOLECULAR PATHOGENESIS  
Gastric  cancer  is  a  heterogeneous disease, and  gastric  carcinogenesis  is  
a  multistep  process  involving   multiple  genetic and epigenetic alterations  
associates  with  environment  conditions. Infections  usually  initiates  
chronic  inflammation  which  initiates  sequence  of  reactive  changes,  
which  prone  to development  of  carcinoma.  The  molecular pathogenesis 
of gastric carcinoma  is  well exemplified  in  the  pathogenesis  of  colonic  
cancer  and  also  noted  in  intestinal  type  of  stomach  cancer
108
. But  it  is  
well demonstrated  in  the precancerous cascade
109
.The established sequence 
of molecular events that occur during the development of   gastric carcinoma  
is  shown (Figure 28) 
 
 
 
 
 
 
 
Figure 28  Multi  step  molecular  pathogenesis  of  Gastric  cancer 
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The most common changes, whether genetic or epigenetic, that occur 
during the development from inflammation to carcinoma are clustered at 
genes involved in cellular regulatory pathways. 
  The four  important  pathways  narrated  here  are interrelated with  
each  other  and  they  are  not considered to  be  independent, as these  
components interact  with  each  other  and  control  the   cellular growth and 
proliferation. 
Oncogenes  and  Tumour  suppressor  gene 
1. The p53 is  the  most  commonly  mutated  tumour  suppressor  gene  
which  controls  the  gene  expression  in  DNA damage, cell cycle 
arrest  to  permit  repairing  of  DNA , or cell apoptosis. Under  
physiological  or  unstressed  situations  it combines with  MDM2 
which  targets  rapid  degradation of p53. Inhibition of  this pathways 
leads to functional activation of p53,  and  it  undergoes  several  post 
–transcriptional  modifications  which  induces cell cycle and  
apoptosis  arrest via p21. TP53  mutation or  LOH  has been reported  
around  60% of all gastric cancers
108
.  Mutation of p53  can  occurs  in  
earlier  part  of  tumoriogenesis  and  also  increases  during  the  
progression  of  cancer.  But  it  is  rarely  found  in  early  gastric  
lesions
110
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2. G1  phase  of  cell  cycle  regulated  by   RB1 (retinoblastoma) 
pathway genes  and  p16  genes. Decreased  expression of p16  found  
in  47% of gastric cancers.
111
 
3. The TGF-"R2 (transforming growth factor – type 2  receptor ") gene is 
particularly susceptible to microsatellite instability, which  leads  to  
loss  of  growth  inhibition,  which  considered  to  be  a  most  
important  feature  of  gastric carcinoma
112
. 
4. The APC (adenomatosis polyposis coli) " has a higher  frequency of 
mutation in 20 – 70% of  gastric  adenoma and flat dysplasia. Their  
importance is  less  established  in  the  development  of  gastric  
carcinoma  when  compared  to  colorectal  cancer.  
Micro satellite  instability (MSI) 
Dysfunction  and  inactivation  of  the  DNA  mismatch  repair  system 
is  responsible  for  MSI.  The   estimated   frequency  of  Micro satellite  
instability  to  be  around  30%  in  gastric  adenocarcinoma. LOH  of  the  
APC , cytosine – adenine  repeat  instability  have  been  documented  in  
well  differentiated  carcinoma.
113
 
Microribonucleic acids (miRNAs) 
miRNAs  can  act  as   both  oncogenes  and  tumour  suppressor  
genes,  which  regulates  multiple  biological  processes. They  are  usually  
found  within  the  regions  of   LOH,   amplification, genomic  regions  
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which  is  associated  with cancer.  Dysregulation  of  miRNAs  plays  an  
important  role  in  gastric  carcinogenesis. Recent  Studies  have  shown  
microRNAs  that  function  as  tumour  suppressors (miRs-101 , miRs-181 , 
miRs-486, miRs-449) were  down regulated, whereas  miRNAs  that  
function  as  a  oncogenes (miRs -21 , miRs-17 , miRs 106a)  were  up 
regulated  in  gastric  carcinoma.
117\4
  Intestinal (27%)  type  of  gastric  
carcinoma  can  be  associated  with  β- catenin  mutations
 115
. 
E–cadherin and the Wnt system 
Wnt  signal transduction pathway is a central mechanism for 
regulating gene expression.  β-catenin normally binds to the intracellular 
domain of E-cadherin (Figure 29).In the absence  of  Wnt  ligand , the 
destruction complex (GSK3β, APC, Axin) creates a hyperphosphorylated β-
catenin, which is a target for Ubiquitination and degradation by the 
proteasome. Binding of  Wnt  ligand to a Frizzled/LRP-5/6 receptor complex 
(right panel) leads to stabilization of  hypophosphorylated β-catenin. Then it  
interacts with TCF/LEF proteins in the nucleus to activate transcription, 
where it  can exert oncogenic role. The whole Wnt pathway becomes   
independent of E-cadherin expression, if  there  is  any  alteration in Wnt  
pathway
103
. This accumulation of β-catenin can be explained by mutations in 
APC gene (Adenomatous Polyposis Coli) or in β-catenin gene itself. E-
cadherin binds to the actin cytoskeleton via a series of catenin proteins. Loss 
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of E-cadherin complexed to the cell membrane is associated with an increase 
in the share intracytoplasmic and nuclear of β-catenin
106
.A mutation of the 
APC gene appears be found in approximately 30% of intestinal  
adenocarcinomas
107
. To further support the role of Wnt, has observed that 
patients with germline mutations of APC present a risk of developing gastric 
cancer 10 times higher than that of the normal population. 
 
Figure 29.The Wnt signaling pathway. 
 
Chromosomal  instability(CIN) 
Gastric  carcinoma  which  is  sporadic  in  nature  has  been  
associated  with  CIN,  Multiple  factors  have  been  contributed  to  CIN  in  
gastric  cancer  patients,  which  includes    DNA  damage  response, 
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H.pylori  infection,  aberrations  in  chromosomal  segregation,  dietary  
nitrates
116
.  It  may  manifest  as  loss  or  gain   of  part/whole  of  
chromosomes. A  higher  frequency  of  LOH  was  found  in  p53, APC,  Rb 
loci and  nm23. 
Epigenetic  changes 
DNA  methylation,  histone  methylation  and  histone  acetylation  
which  has  been  recently  documented  epigenetic  alterations  leads  to  
gene  alterations. 
(i)DNA  methylation 
             Silencing  of  tumour  suppressor  genes  may  occur  when  it  is  
associated  with  hypermethylation  of  CpG  islands,  which  have  been  
identified  in  gastric  carcinoma  that  serve  as  a  good  prognostic  
indicators
117
.  Mutations in E-cadherin ( member  of  the  APC  pathway) 
have been  recognised  in 50%of diffuse-type of  gastric  cancer.
108
 
(ii) Histone  acetylation 
Histone  deacetylation  is associated  with  transcriptional  repression  
of  multiple  tumour  suppressor  genes  by  inactivating  chromatin. 
Hypoacetylation  of  histones  H4 & H3  in p21 promotor  region  is  
observed  in  more  than  50%  cases
118
.  70%  of  gastric  carcinoma  
expresses  reduced  level  of  acetylated  histones  H4.  
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As  discussed  above, the  components  affected  by  mutation varies. Each  
patients  with  gastric  carcinoma  expresses  different combinations of 
mutations, often in tumours with  same  histological  type. Even  same  type  
of    tumours  react  differently  to  treatment. Each  cancer  exhibits  its  own  
array  of  genetic  alterations  which  leads  to  tumoriogenesis  and  it  shows  
high variability. Although   many  tumour suppressor genes  and  oncogenes  
are  discovered  so  far, there  is  still  need  for  evaluation  and  detection  of  
genes  which  involved  in  the  cellular  pathways .A wide  genomic  
research  is  required  to  detect  the  novel methylation silenced genes  in  
gastric  cancer, which will help  to  understand  molecular genetics  of GC 
and  to  provide  new  treatment  opportunities. 
TREATMENT 
1. Curative resection 
Even  in  the  absence  of  metastatic  spread,  aggressive  surgical  
resection  of  gastric  tumour  is  justified.  Curative  resection  (R0) is  
defined  as  a  complete  resection  of  tumour  with  resected  margin  free  
of malignancy, both  grossly  and microscopically
119
.R1  is  known  as  
resection with residual microscopic disease, and  R2  is  known  as  resection 
with gross residual disease.  Survival  rate  is  good  in  patients  who  
underwent  R0  resection  for  local disease. Several  published studies  
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described  that   the  curative surgical management determined  by the 
surgeon  is a most  important, independent prognostic factor 
120
.   
Gastrectomy procedures  which  includes total gastrectomy, subtotal 
gastrectomy and  proximal  total  gastrectomy.  Tumours  located  in  the  
antrum  an  distal  body  can  be  resected  by  subtotal  gastrectomy.  
Tumours  originated  from  the  cardia  resected  by  proximal  total  
gastrectomy. 
2. Lymph node dissection 
Involved  lymph  nodes  also  requires  to  be  removed  along  with  
radical  and  curative  resection. The incidence of  nodal  involvement  which  
ranges from3% to 5% for tumours  restricted  to the mucosa, 16% to 25% for 
tumours  confined to submucosa, and 80% to 90% in patients with  stage III 
or stage  IV disease. The  extent of lymph node dissection (LND)  is  not  
well  defined. There is also no convincing evidence that extended lymph 
node dissection, as advocated by some Japanese surgeons, significantly 
increases survival.
121
 
The  five-year  survival  rates  of   the extended LND  is  increased  
when compared  to  limited  resections. A minimum of 15 lymph nodes 
should be sampled by the surgeon and reported by the pathologist for an 
adequate pathological staging.
122
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Gastric carcinoma responds little to radiation therapy andit  is also 
relatively unresponsive to chemotherapy.
123,124
 Recently, HER2/neu  has 
been validated as a molecular target for this disease.
125
 
3.Palliative  treatment  
      The  goal  of  palliative  treatment  is  to  relieve  the  pain  with  minimal  
morbidity.  Surgical  palliation  usually  done  for  advanced  gastric  
tumours, which  includes  surgical  resection,  bypass  alone  or  in  addition  
with  endoscopic  and  radiotherapy  technique. Complete  staging  of  
tumour  is  necessary  to  select  the  proper  method  of  palliation  for  
individual  patients.    
STAGING OF GASTRIC CANCER : 
The TNM staging system (Annexure III) is widely used in western 
countries. It is the best available predictor of prognosis and is recommended. 
PROGNOSTIC FACTORS 
Prognostic factor is defined  as any variable  pathological  factor   that  
provides   useful   information  to  assess  the  outcome  of  disease  at  the  
time  of  diagnosis. These  pathological  factors  are  TNM  staging,  
macroscopic  type  of  tumours,  site  of  tumour  origin, histological  type,  
nodal  involvement, vascular  invasion,   lymphatic  invasion.
126 
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Age and Gender 
Gastric  carcinoma  is  common  among  males  than  females(2:1) in  
elderly  patients
127
. The  gender  difference  is  usually  not  seen  in  young  
individuals. Gastric  cancer  usually  diagnosed  around  the  age  of  60 – 70 
years.  Increased  incidence  of  gastric  cancer  is  found  in   older  
individual. These  gender  differences  usually  not  seen  in  younger  
patients  and   10%  of  gastric  cancer  may  occurs  around  the  age  of  40 
years.
127-129
 In younger  patients  with  gastric  cancer  are  more  prone  to 
diffuse  type  of  carcinoma
130,131
. Some  studies  published  that   prognosis 
of  gastric  cancer  does  not seem  to  be affected  by age, once  the  survival 
data  is adjusted for TNM stage.
131,132
 
Grade 
Pathologic  grading  system  classifies  tumours  into 3 categories. 
They  are  well  differentiated,  moderately  differentiated  or  poorly  
differentiated. This  degree  of  differentiation  has  been  shown  to  
correlate  with  the  aggressive  forms  of  malignancy.
133
  Even  though  
grade  is  usually  reported  in  pathological  reports, their  significance  in  
gastric  carcinoma  remains  unclear. Several  published  studies  failed  to  
conclude pathological  grade as  an  independent  prognostic factor
134-136
. 
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Size 
Several  retrospective  studies  revealed  prognosis  is  associated  with  
the  size of  the  tumour.
136 -138
Even though  it  is  one  of  the  powerful  
predictor  of  prognosis,  it  doesn’t  seems to   have  a  prognostic 
significance when compared  with  depth  of   penetration and  nodal  
metastasis.
139 
Tumour Location 
The location  of  the   tumour  has  a several valuable  implications  in  
the  management  and  prognosis of gastric cancer. Several  studies  has  
demonstrated  gastric  cancer  originates  from  proximal  stomach shows  a  
distinct  clinical entity  and  prognostic  association.
137-141
  Few  studies  
failed  to  find  association between  tumour  location and prognosis
142
. A  
recent study  published  that  tumours located  in  proximal  stomach  have  
extensive  gastric  wall  penetration, vascular  invasion, lymph  node  
metastasis, advance  stage, with an overall poor  survival  rate  when  
compared  to  distal tumors.
140
 So  that  different  surgical  approach  is 
required  for  proximal  tumours  because  of  its  aggressive  biological  
behaviour. 
Lymphatic and Vascular Invasion 
Recently,  studies  related  to  lymphatic  and  vascular  invasion 
gained popularity  for  predicting  tumour  behaviour. Studies have shown  
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that  nodal  involvement  is  important  predictor of survival, and  the 
existence  of  tumour  emboli , significantly  raises  the  recurrence  of  
tumour  and  death  even  after  curative  resection.
138,143
 They  are  usually  
associated  with  decreased  survival rates.
 
TNM Staging 
TNM  is the most significant prognostic factor. One of the features  
that  it  incorporates is the degree  of  infitration
144
. Tumours  with  increased  
depth  of  invasion  have  the  greater  chance of metastasis. This feature is 
related  to the  macroscopic  appearance  of  the  tumour. Tumour grows  
primarily  within  the  gastric  wall  have  a higher  incidence  of  metastasis  
than  the  intraluminal  neoplasms. Five  year  survival  rates  are  91%  for  
stage Ia  tumours, 64%  for  stage II tumours, 27%  for  stage  IIIa  tumours, 
and  0%  for  stage  IIIb/IV  tumours
144
. 
And  Survival rate of  patients with  EGC  invading mucosa  but  
limited submucosa being 90-100%, compared  with  60-80% for  gastric 
tumours invading the  muscularis propria, and  41-50% for  tumours which  
is  limited to the subserosa or serosa.
144,145
Survival  rate  for  advanced  
gastric  carcinoma is  lower than 23% ,   and  the  prognosis of  this advanced  
lesions remains poor.
145 
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Lymph node metastasis  
  The  depth of   tumour  invasion   correlates  with the presence nodal 
metastasis, and  the  presence of  regional  nodal  metastasis  decreases  the  
five year survival  rate of  EGC  from  90% to 70%. The  lymph  node  status 
and  the  ratio of  involved  and  uninvolved lymph nodes  are the important  
markers of gastric carcinoma prognosis.
126
  The  Nodal  ratio (N-ratio)  has 
been recognised  as an important  independent  prognostic factor,  even  
where  less than  the  fifteen  lymph nodes  have  beenanalysed.
146
 The five  
year  survival rate  is  44%  for  patients with 1-6 lymph nodal  metastases, 
30%  for  7-15 nodal  metastases,  and  11%  if  more than 15 lymph nodes 
shows  deposits. And  five  year  survival  rate  is  83.4%  for  the  cases  
showed  zero  N ratio, if  the  N ratio  is  1  the  survival  rate   could  be 
66.3%  , 46  %  for  the  cases  showed  N  ratio  2 , and 19.0%  survival  rate  
for  the  N-ratio 3.  Unfortunately,  most  of  patients with  advanced  gastric  
carcinoma  already  presents  with  nodal  metastases. 
Histological classification  
Diffuse type  of  gastric  tumours  and  mucous-rich  tumours may  
predict a  poor prognosis
1 
Borrmann’s classification 
Borrmann  has  categorized  the  gross  appearance of  gastric tumours 
into four types.
147 
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Borrmann type IV cancer usually  shows  an unfavourable 
prognosis.
155,156
 
Other Factors 
Multiple  other  factors  have  been  associated  with  higher  incidence  
of  local recurrence and  reduced  survival.  Tumour  markers like  p53,  CD 
34, E-cadherin, HER2/neu,  CA 72–4,  CEA   have  been  considered  as  
potential  prognostic  markers  for  predicting  the  behaviour  of  tumor
140, 
150,151
 The  recognition  of  reduced  expression  of  E-cadherin  act  as an 
indicator of  worse  prognosis.
152,153
 The  impact of additional  molecular 
genetic alterations over  the  prognosis of  gastric carcinoma  is currently the 
field  of  interest
154,155
 
Human epidermal growth factor 2(HER2/ neu) 
TNM  stage  is  the  most  important  factor  in  determining  the  
prognosis  of  gastric  cancer.   However,  in  patients  with  the  same  stage,  
prognosis  could  be  various, so  further  research  studies  are  needed  to  
identify  new prognostic  factors. 
HER-2  is  a  proto oncogene,  which  is   located  on chromosome 17q 
and encodes a transmembrane tyrosine  kinase receptor protein that is a 
member of the epidermal growth factor receptor (EGFR) or HER family 
(Family 30)
154
  which  involved  in  various  solid  tumour  such  as  breast  
tumours,  colorectal  cancers  and  gastric  carcinoma.
156,157 
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Although  a  ligand for  HER-2/neu  protein  has not been  recognised, recent 
published  studies suggest that  HER-2/neu  is the preferred   heterodimeric  
partner  in  the  family  of  epidermal growth factor receptors. The tyrosine  
kinase  activity  of  HER-2/neu intracellular  domain  triggers  signal 
transduction pathways, which are involved in cell proliferation, migration, 
apoptosis, and differentiation
179
. 
 
Figure 30 HER (erb)  family,  HER-2/neu  has  no  known  ligands 
IMMUNOHISTOCHEMISTRY: 
               Albert Coons et al in 1941 first labelled antibodies directly with 
fluorescent isocyanate. Nakane and Pierce et al in 1966, introduced indirect 
labelling technique in which unlabelled antibody is followed by second 
antibody or substrate. Various stages of development of 
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Immunohistochemistry include peroxidase – anti peroxidase method (1970), 
alkaline phosphatase labelling (1971), avidin biotin method (1977)  and two 
layer dextrin polymer technique (1993)
158
 
ANTIGEN RETRIEVAL: 
             Antigen  retrieval  can  be  done  by the following different 
techniques to  unmask the antigenic determinants of fixed tissue sections. 
1. Proteolytic enzyme digestion 
2. Microwave antigen retrieval 
3. Pressure cooker antigen retrieval 
4. Microwave and trypsin antigen retrieval 
PROTEOLYTIC ENZYME DIGESTION: 
Huank et al in 1976  has  introduced this technique to breakdown 
formalin  cross linkages and to unmask the antigen determinants. The most 
commonly  used  enzymes include trypsin and proteinase. The disadvantage 
includes  over digestion, under digestion and antigen destruction. 
MICROWAVE ANTIGEN RETRIEVAL: 
            This is a new technique most commonly used in current practice. 
Microwave oven heating involves boiling formalin fixed paraffin sections in 
various buffers for rapid and uniform heating. 
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PRESSURE COOKER ANTIGEN RETRIEVAL: 
Miller et al in 1995 compared and proved that pressure cooking 
method has fewer inconsistencies, less time consuming and can be used to 
retrieve large number of slides than in microwave method 
PITFALLS OF HEAT PRETREATMENT: 
Drying of sections at any stage after heat pretreatment destroys 
antigenicity. Nuclear details are damaged in poorly fixed tissues. Fibers and 
fatty tissues tend to detach from slides while heating. Not all antigens are 
retrieved by heat pre treatment and also some antigens like PGP 9.5 show 
altered staining pattern. 
DETECTION SYSTEMS:  
             After addition of specific antibodies to the antigens, next step is to 
visualize the antigen antibody reaction complex. The methods employed are 
direct and indirect methods. In the direct method, primary antibody is 
directly conjugated with the label. Most commonly used labels are flouro-
chrome, horse radish peroxidase and alkaline phosphatase. Indirect method 
is a two-step method in which labelled secondary antibody reacts with 
primary antibody bound to specific antigen. The use of peroxidase enzyme 
complex or avidin biotin complex further increases the sensitivity of  
immunohistochemical stains
158
. 
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In 1993, Pluzek et al introduced enhanced polymer one step staining, 
in which large numbers of primary antibody and peroxidase enzymes are 
attached to dextran polymer back bone. This is the rapid and sensitive 
method
159.
Dextran polymer conjugate two step visualization system is based 
on dextran technology in Epos system. This method has greater sensitivity 
and is less time consuming.
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MATERIALS & METHODS 
This study was proposed and conducted in the Department of 
Pathology of   Tirunelveli  Medical College Hospital after due approval of 
the TVMC Research Ethical Committee. The study sample comprised of 
gastrectomy specimens received at the Surgical Pathology division of the 
Department of Pathology, Tirunelveli Medical College Hospital, during the 
period from January 2012 to August 2014.A sample of 50 patients who were 
diagnosed as  having gastric adenocarcinomas were selected for this study 
based on a set of inclusion and exclusion criteria. 
INCLUSION CRITERIA 
Gastrectomy specimen diagnosed as previously  Gastric 
adenocarcinoma by  endoscopic  biopsy. 
EXCLUSION CRITERIA 
Specimens  diagnosed  as  non  epithelial  tumours, secondary  
tumours, small cell carcinoma, squamous  cell carcinoma   were  excluded. 
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Methodology 
1. Patients who had a gastrectomy done were included in this study as 
per inclusion and exclusion criteria and their clinical data was 
recorded in a piloted  Pro Forma (ANNEXURE I ) 
2. All gastrectomy samples received were fixed in10% neutral buffered 
formalin as per standard procedure and processed as per standard 
protocols (Annexure IV), then embeddedin paraffin  wax. Then 3-5 
micron thickness sections were cut and stained with H&E as per 
standard protocols (ANNEXUREII).  
3. The histological features were recorded in the study pro-forma and a 
detailed histomorphological diagnosis was arrived at. 
4. The  histomorphological data was correlated with the patient’s  
clinical  data like site  of  tumour, radiological  details etc.  
5. Tumours were histologically classified  as per WHO  classification. 
6. The blocks were studied and representative sections were identified 
for immunohistochemistry.  
7. Thin 3micron sections were cut and were stained with HER-2neu 
antibody as per standard protocol as follows (ANNEXURE IV). 
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Consensus recommendations on HER-2 scoring for 
gastric  cancer. 
(Table6) 
Definition Score 
No reactivity or membranous reaction in <10% of cells 0 / negative 
Faint /barely  perceptible  membranous  reactivity in 
>10% of cells 
Cells are reactive only in part of their membrane 
 
1+ /negative 
Weak to moderate  complete or basolateral membranous 
reactivity in >10% of cells 
2+ 
/equivocal 
Moderate to strong complete or basolateral membranous 
reactivity in >10% of cells 
3+ /positive 
 
A strong brown staining was located in cell membrane of malignant 
cells using this staining method. The Thermo Fisher Scientific (Cheshire, 
UK) Test Protocol System was used to grade the membrane staining. We 
used membrane stain graduation scale for assess the IHC. It  is  graded  0, 
1+, 2+, 3+  according  to  the panel  scoring (Table 6 )
160
.  And  approach  to  
the  standardized IHC scoring in gastric cancer summarised.(Figure 31 )
161
 
The IHC stained sections   was examined  and evaluated manually by 2 
pathologists. 
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FIG 31  APPROACH TO IMMUNOHISTOCHEMISTRY  SCORING IN GASTRIC CANCER  SAMPLE 
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Statistical analysis 
The  correlations  between  HER2/neu  status  and  patient  clinico 
pathological  data  was  evaluated  by  using  fisher  t  test  and  chi- square  
test.  p  value  less  than  0.05  considered  to  be  positive. Data  has  been  
analyzed  by  using the SPSS statistical software program (Version 19.0)for 
Microsoft Windows  7. 
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OBSERVATION AND RESULTS 
Gastrectomy samples of 57 patients for gastric carcinomas were  received at 
the surgical pathology division of the Department of Pathology between 
January  2012  and August  2014.  Of  these 57 patients ,  52  (91.2%)   had 
gastric adenocarcinoma  in  histopathological examination.(Table 7 ) 
TABLE  7 
Gastrectomy Specimens Received(n) 57 
Gastric Adenocarcinoma(n) 52 
GIST(n) 3 
Gastric Non Hodgkins Lymphoma(n) 2 
 
Of   the  52  patients  with  adenocarcinoma  of   the  stomach,  2  
patients  were  not  included  in  further  study.  Two  cases  excluded  from  
the  study  because  of  non  availability  of  pathological  blocks. (Table8) 
TABLE 8: THE STUDY GROUP 
Primary  Gastric  Adenocarcinoma(n) 52 
No   Of  Cases  Selected  For  Study (n) 50 
No  Of  Cases  Not  Selected  For  Study (n) 2 
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These 50  cases  were  studied for  Her 2/neu expression. Her 2/neu 
expression   was  found  to  be correlated  with  the clinicopathologic  
parameters. Of these 50 cases,45  cases comprised  of  subtotal gastrectomies 
and  the  remaining  cases  were subtotal  gastrectomies   as  mentioned  on  
Table 9. 
TABLE 9: TYPE  OF  SURGERY 
 
 
 
 
 
 
Of  these  50 cases  which  were  studied   for  the  HER2/neu  
reactivity, 4 cases showed  3+ (8%) ,  4  cases showed  2+ (8%)  , 16  cases  
showed  1+(32%),  and  26  cases (52%)  did  not  show   reactivity 
(negative)  as  per the  scoring  system  devised  by   Hofmann  scoring  
system
177
(Table 10) 
TABLE 10. HER2/neu   REACTIVITY IN THIS STUDY 
HER2/neu score Number  of  cases (n) Percentage(%) 
0 26 52 
1+ 16 32 
2+ 4 8 
3+ 4 8 
Gastrectomy  Total cases(n) 
Subtotal   44 
Total  6 
TOTAL  50 
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TABLE 11: GENDER  OF PATIENTS &HER2 neu EXPRESSION 
Gender Total  cases( n) HER2 neu negative(n) HER2  neu 
positive(n) 
Male         34                   29 5 
Female         16 13 3 
Total        50 42 8 
 
Of   the  50  cases  of   gastric  adenocarcinoma,  34  cases  were   
male  and  16  were  female.  Out  of  34  male  cases,  5  cases  (14.7%)  
were  HER2/neu positive. Of  the  16  female  cases,  3  cases  (18.75%)  
were  positive   for  HER2/neu   expression.(Table 11&  Chart 1) 
TABLE 12 : AGE OF PATIENTS &HER2/neu    EXPRESSION 
 
Age  
 
Total  cases(n) 
 
HER2 neu negative(n) 
 
HER2 neu positive(n) 
<57            22 20 2 
≥57             28 22 6 
Total            50 42 8 
 
Among  the  50  cases,  22  patients  were  less  than  median  age  of  
57  years  and  of  which  2  cases  (9.1%)  positive  for  HER2/neu.  28  
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patients  were  above  the  median  age,  of  which  6  cases  were  positive  
(21.43%)  for  HER2/neu  expression.(Table 12&  Chart 2) 
TABLE 13: LOCATION  OF  TUMOUR  &HER2/neu  EXPRESSION 
 
 
Among  the  50  cases, in   17  cases   tumour   were  located  in  
corpus  and  OGJ,  of  which  two  cases  tumours  originated  from  
oesophagogastric junction. From  these  6  cases  (35.3%)  found  positive  
for  HER 2/neu  expression. In  33  cases  tumour  were  located   in  pyloric  
antral  region,  of   which  2  cases  (6.06%)  were  positive  for  HER2/neu  
expression.(Table 13&  Chart 3) 
 
 
 
 
Tumour 
Location  
Total 
cases(n) 
HER2 neu 
negative(n) 
HER2 neu 
positive(n) 
Body & OGJ 
 
17 11 6 
 
Pyloric 
antrum 
 
33 
 
31 
 
2 
 
Total 
 
50 
 
42 
 
8 
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TABLE 14:    TUMOUR  SIZE&HER2/neu  EXPRESSION 
Tumour Size Total cases(n) HER2 neu 
negative(n) 
HER2 neu 
positive (n) 
<5 cm 22 19 3 
≥ 5 cm 
 
28 
 
23 5 
Total 
 
50 
 
42 8 
 
The  gastrectomy   specimen   examined,  and  it   was  correlated  that  
of  the  50  patients  studied  22  patients  had  a  primary  tumour  size  of  
less  than that  of  median  tumour  size  5cm,  of  which  3  cases(13.6%)  
shows  positive for  HER2/neu  expression.  28  patients   had  a  primary  
tumour  size  of  more  than  5cms,  of  which  5  cases(17.9%)  shows  
positive  for  HER2/neu  expression.(Table 14&  Chart 4) 
TABLE 15:  LAUREN’S   CLASSIFICATION  &   HER2/neu  EXPRESSION 
Lauren's 
classification 
Total  
cases(n) 
HER2 neu  
negative(n) 
HER2 neu 
positive(n) 
Intestinal           32 28 4 
Diffuse           18 14 4 
Total           50 42 8 
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50  Cases  of  gastric  adenocarcinoma  were  grouped  into  2  according   to  
Lauren’s   classification,  out  of  which  32  cases  belonged  to  intestinal  
type  and  18  cases  belonged  to  diffuse  type.  Out  of  the  32  cases  of  
intestinal  type ,  4  cases (12.5%)   found  to  be  positive  for  HER2/neu 
expression. And  4 (22.22%)   cases  out  of  18  cases  of  diffuse  type  
shows  positivity  for HER2/neu  expression.(Table 15&  Chart 5) 
TABLE 16 :  WHO  CLASSIFICATION  &  HER2neu  EXPRESSION 
HISTOLOGIAL 
TYPE 
TOTAL  
CASES(n) 
HER2 neu 
NEGATIVE(n) 
HER2 neu 
POSITIVE(n) 
TUBULAR 23 20 3 
PAPILLARY 7 6 1 
MUCINOUS 2 2 0 
SIGNET 10 6 4 
DIFFUSE 8 8 0 
 
Among  histological forms, 13% of tubular carcinomas, 14.2% of 
papillary carcinomas, 40%  of  signet ring cell  carcinomas showed   
HER2neu  expression.  Mucinous  carcinoma  and  diffuse  type  carcinoma  
showed  negative  for  HER2neu  expression.  (Table 16  and Chart 6 ) 
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Table 17:  LYMPH  NODAL  STATUS  &HER2/neu  EXPRESSION 
Nodal 
status   
Total 
cases(n) 
HER2 neu 
negative(n) 
HER2 neu 
positive(n) 
           N0              13 13 0 
           N1              14 12 2 
           N2              16 11 5 
           N3                 7 6 1 
 
The  gastrectomy  specimen  were  examined  and  correlated.  Among  
these  50  patients  studied,  13  patients  had  no  nodal  involvement (N0)  
and  none  of  the  cases  were  shown  HER2/neu  positivity.  14  cases  had  
N1  level  lymph  node  metastasis,  of  which  2  cases(14.3%) shows 
positive  for  HER2/neu  expression.  16  cases  had  N2  level  lymph  node  
metastasis,  of  which  5  cases(31.25%)  positive  for  HER2/neu  
expression.  7  cases  had  N3  level  lymph  node  metastasis,  of  which  1  
cases(14.28%)  positive  for  HER2/neu expression.(Table 17&  Chart 7) 
TABLE 18:  LYMPH  NODE  RATIO  &HER2/neu  EXPRESSION 
Lymph node 
ratio 
Total  cases(n) HER2 neu 
negative(n) 
HER2 neu 
positive(n) 
<0.5 23 21 2 
≥0.5 27 21 6 
 
Total 
 
50 
 
42 
 
8 
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Lymph  Node  Ratio (LNR)  defined as the ratio of  lymph nodes with 
tumour metastasis to the total lymph nodes dissected. 
The  median  of  the  total  received  lymph nodes  were  found  to be  
5,  and  the  median  number  of  involved  lymph  nodes  were   2.  The  
ratio  of  the  involved  and  uninvolved  lymph  node  was  0.5.  Among  50  
cases,  23  cases  had  0.5  LN  ratio, of  which   2  cases  (8.7%)  showed  
positivity  for  HER2/neu  expression.  And  27  cases  had  more  than  0.5  
LN  ratio, of  which  6  cases (22.22%)  showed  positivity  for  HER2/neu  
protein. (Table 18&  Chart 8)  
TABLE 19: RESECTED  MARGINS&HER2 neu EXPRESSION 
 
Resection 
Margin 
 
Total cases 
(n) 
 
HER2  neu 
negative(n) 
 
HER2 neu 
positive(n) 
R0 30 26 4 
R1 1 1 0 
R2 19 15 4 
TOTAL 50 42 8 
 
Out  of  the  50  cases  studied, 30 cases shows  no  tumour  
involvement  in  the  resected  margins.  Among  these 30 cases,  HER2/neu 
expression   was  observed  in  4  cases (13.33%).  Only  one  case  had  
shown  a  feature  of  microscopic  positivity  for  tumour(R1), of  which  
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none  of   the  cases  showed   HER2/neu  expression.19  cases  had  shown  
gross  residual   disease (R2),  of   which  4  cases(21.05%)  were  positive 
for   HER2/neu expression.(Table 19&  Chart 9) 
TABLE 20:  LYMPHATIC  INVASION&HER2 neu  EXPRESSION 
Lymphatic 
invasion 
Total 
cases(n) 
HER2  neu negative 
(n) 
HER2  neu 
positive(n) 
NO 16 15 1 
YES 34 27 7 
TOTAL 50 42 8 
 
Lymphatic  invasion  characterized  as  a  embolus  of  carcinoma cells  
or  infiltration  of  carcinoma cells  as  single/ tiny clusters  in  lymphatic  
capillaries  or   interstitial  space of  perilymphnodal fat tissue  Among  50  
cases  of  gastric  adenocarcinoma,   34  cases  showed  lymphatic invasion. 
Out  of  34  cases,  HER2/neu  expression  was  noted  in  7  cases  (20.6%).  
And  16  cases  without  lymphatic  invasion  also  shows  6.25% (1 case)  
positivity  for  HER2/neu  expression.(Table 20&  Chart 10) 
TABLE 21: SEROSAL   INVASION &HER2 neu  EXPRESSION 
Serosal 
Invasion 
Total 
cases(n) 
 
HER2  neu  
negative(n) 
 HER2 neu 
positive(n) 
     No 27 21 6 
     Yes  23 21 2 
     Total  50 42 8 
Serosal  invasion  characterized as tumour  invading  into  visceral  
peritoneum or  tumour present at the peritoneal surface with  inflammatory  
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reaction/mesothelial hyperplasia/ ulceration  or tumour cells demonstrated 
free in  peritoneum with  the  evidence of adjacent ulceration. 
Among  50  cases  with  gastric  adenocarcinoma,  2  out  of  23  cases 
(8.7%)  with  serosal  invasion   were  positive  for  HER2  expression,  
while  6  out  of  27  cases (22.22%)  without  serosal  invasion  showed  
positivity  for  HER2  expression.  (Table 21&  Chart 11) 
TABLE 22 : PERINEURAL   INVASION &HER2 neu  EXPRESSION 
 
Perineural 
Invasion 
 
Total 
cases(n) 
 
 
HER2 neu  negative 
(n) 
 
HER2 neu  
positive (n) 
             No            36 32 4 
             Yes              14 10 4 
            Total             50 42 8 
 
Perineural  invasion (PNI)  is  a  process of  neurotropic  
carcinomatous  spread  and  perineural  spread.    
Among  50  cases  with  gastric  adenocarcinoma,  4  out  of  14  cases 
(28.6%)  with  perineural  invasion   were  positive  for  HER2  expression,  
while  4  out  of  36  cases(11.11%)  without  perineural  invasion  showed  
positivity  for  HER2  expression.(Table 22&  Chart 12) 
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TABLE  23: SIGNET CELL CARCINOMA &HER2 neu  EXPRESSION 
 
Histological 
type 
Total 
cases(n) 
HER2  neu 
negative(n) 
   HER2  neu 
positive(n) 
SRC 40 36 4 
NON  SRC 10 6 4 
Total 50 42 8 
 
Signet  ring  carcinoma (SRC)   defined as an adenocarcinoma in 
which predominant  component  (more than 50% of  the tumour  cells)made 
up of isolated or small groups  of  neoplastic  cells  containing  
intracytoplasmic mucin. 
Among  50  cases  of  gastric  adenocarcinoma,  4  out  of  40  cases 
(10%) without  signet  cell  features    were  defined  as  positive  for  HER2  
expression,  while  4  cases  out  of  10  cases (40%)  with  signet  cell  
features  showed  positivity  for  HER2 expression .(Table 23&  Chart 13) 
TABLE 24 : TNM  STAGING &HER2 neu  EXPRESSION 
TNM 
stage 
Total cases(n) HER2  neu negative 
(n) 
HER2  neu positive (n) 
stage I 6 6 0 
stage II 24 21 3 
stage III 20 
 
15 5 
Total 50 
 
42 8 
TNM ( Tumour- Node-Metastasis)  Staging  is  the  widely  used,  
recommended  staging  system for gastric cancers. It  has  been  revised  
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according  to UICC  guidelines( 7th  edition).  This  new  classification  was  
based  on  the  number  of  positive  regional  lymph  nodes  instead  of  the  
anatomic location  of  the  regional  lymph  node  metastasis, which  was  
mentioned  in  (Annexure III)  
Of  the  50  cases  studied  all 50  patients  (100%)  had  gastric  
adenocarcinoma.  According  to  seventh  edition  of  UICC  guidelines,  
pTNM   staging  of  50  cases  were  done
189
.  Stage  evaluation  revealed  
that  6  cases   falls  under  stage  I,  24  cases  in stage II &  20  cases  in  
stage  III.  5  out  of  20  cases  in   stage III(25%)  had  shown  positive  for  
HER 2  expression.  3  out  of  24  cases(12.5%)  in  stage II  were  defined  
positivity  for  HER2  expression,  while  none  of  the  stage I  cases  
revealed   HER2 expression.(Table 24&  Chart 14) 
 
 
 
 
 
 
 
 
 
  
89 
 
 
 
CLINICPATHOLOGICAL PATIENT CHARACTERISTICS (Table 25,26,27,28) 
In  this  study  all  50  cases  fulfilled  study  criteria  were  included. 
Clinicopathological  characteristics  are  mentioned  in  following  tables. 
PATIENT CHARACTERISTICS (TABLE 25) n =50 
Patients (n) 50 
Age(years)  
Mean 55.66±10.53 
Median 57 
Gender, n (%)  
Men 34 (68) 
Women 16 (32) 
Lauren phenotype, n (%)  
Intestinal  32 (64) 
Diffuse 18 (36) 
Histological type, n (%)  
                   Tubular 23(46) 
                   Papillary 7(14) 
                   Mucinous 2(4) 
                   Signet 10(20) 
                   Diffuse 8(16) 
 
PATIENT CHARACTERISTICS (TABLE 26) n =50 
Localisation, n (%)  
Body& OGJ 17 (30) 
Pyloric antrum 33(64) 
Resected Margins, n (%)  
pR0 30 (60) 
pR1 1 (2) 
pR2 19 (38) 
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PATIENT CHARACTERISTICS (TABLE 27) n =50 
TNM stage(7
TH 
edition) , n (%)  
Stage I 6 (12) 
Stage II 24 (48) 
Stage III 20 (40) 
 
PATIENT CHARACTERISTICS (TABLE 28) n =50 
Resected lymph nodes  
Mean ± SD 5.6±3.94 
Median,n 5 
Positive lymph nodes  
Mean ± SD 3.1±3.55 
Median,n 2 
Lymph node ratio  
Median,n 0.5 
Lymphatic invasion, n (%)  
 pL0 16 (32) 
 pL1 34 (68) 
 
The  median  number  of   resected  lymph  nodes  were  5, and  the  
median  number  of  involved  lymph  nodes  were  2.  The  ratio  between  
metastatic  and  resected  lymph  nodes  (N ratio)  has  been  tabulated.  
Median  of  lymph  node  ratio  was  0.5 
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CLINICOPATHOLOGICAL VARIABLES OF GASTRIC CANCER 
PATIENTS STRATIFIED BY HER-2/NEU  STATUS (Table 29) 
The  medical  records  of  each  case  was  reviewed  and  medical , 
demographic  and  pathological  data  of  the  patients  was  collected. Patient  
age  and sex  were  included  in  demographic  data. Tumour  location  and  
TNM  stage  and  treatment  history  were  included  in  Clinical  and  
pathological data.        Table 29 
Parameter HER 2neu 
Negative (n) 
HER 2neu 
Positive (n) 
P-Value 
Age (years)   0.439 
>57 20 2  
≥57 22 6  
Gender   0.699 
Men 29 5  
Women 13 3  
Localisation   0.027 
Body & OGJ 11 6  
Pyloric antrum 31 2  
Tumor Size   1.000 
<5cm 19 3  
≥5cm 23 5  
Differentiation   1.000 
Yes 22 4  
No 20 4  
Lauren’s Classification   0.4357 
Intestinal 28 4  
Diffuse 14 4  
WHO Type   0.174 
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Tubular 20 3  
Papillary 6 1  
Mucinous 2 0  
Signet 6 4  
Diffuse 8 0  
Nodal Status   0.157 
No 13 0  
N1 12 2  
N2 11 5  
N3 6 1  
Lymph node ratio   0.2609 
<0.5 21 2  
≥0.5 21 6  
Perineural Invasion   0.1968 
No 32 4  
Yes 10 4  
Lymphatic Invasion   0.4092 
No 15 1  
Yes 27 7  
Serosal Invasion   0.2609 
No 21 6  
Yes 21 2  
Resected Margins   0.7011 
R0 26 4  
R1 1 0  
R2 15 4  
TNM stage (7
th
 Edition)   0.277 
Stage I 6 0  
Stage II 21 3  
Stage III 15 5  
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 This  study  consist  of  31  males  and  19  females  with  ages  
ranging  between  37  and  80  years . 57  years  stratified  as  a  median  
tumour  age  according  to  this  study.( Refer  table  no 8). 
 Tumour  size  of  5cm  stratified  as  median  tumour  size  according  to  
this  study.( Refer  table  no 9) 
The ratio of metastatic to examined lymph nodes  (LNR) was 
determined, and   HER2neu  expression  is  analysed  in  relation  to  two  
groups  LNR < 0.5, and LNR > 0.5. ( Refer table no 13). 
  HER 2/neu expression is  correlated  with  clinicopathologic  
parameters.  The  50  gastric  cancer  gastrectomy  tissue  specimens  were  
examined  for  the  presence  of  HER 2/neu,  determined  by  
immunohistochemistry.  Of  these  specimens,  6  (12%)  exhibited  
HER2/neu-  positive  expression.   
1. HER 2/neu expression  was  correlated  with  Histological  type-  
signet  ring  cell  carcinoma  with  p  value  < 0.05. 
2. HER 2/neu expression  was  also  correlated with  location  of  the  
tumour.  OGJ  and  corpus  tumours  are  associated  with  HER2 neu  
expression  compared  with  antral- pyloric  tumour  ( p value < 0.05) 
3. There  were no  differences  between  the  groups  in  terms  of  age,  
gender,  type  of  gastrectomy,  tumour  size,  nodal  status,  stage  of  
disease,  perineural  invasion,  serosal  invasion  and  differentiation  
of  tumour. 
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DISCUSSION 
HER2/neu  and  its  ligands  are  frequently  overexpressed  in  human  
cancers.  HER2/neu  protein  is  member  of  the  epidermal  growth  factor  
receptor (EGFR)  family,
162
 and  it  is  a  185 kDa  transmembrane  tyrosine  
kinase (TK)  receptor . HER2/neu  dimerizes  with  either  itself  or  a  
structurally similar  HER2/neu family  member  to  activate a cascade  of  
cellular  pathways  that  contribute  to  cell  growth, proliferation  &  
survival. In  breast  carcinoma , HER 2/neu  amplification / over expression  
has  been  associated   poor  overall  prognosis ,  and  it  shows  resistance  to  
standard  cytotoxic  therapies  and  susceptibility  to  HER2/neu -  targeted  
therapy  such  as  transtuzumab.  Thus  in  breast  carcinoma,  HER2/neu  is  
a  biomarker   that  has  both  prognostic  and  predictive  value
163
. Although  
various  therapies  for  gastric  carcinoma  are  available,  such  as 
gastrectomy  with  extensive  lymphadenopathy  and   surgery  combined  
with  chemotherapy,  the  patients  respond  poorly  to  the  conventional  
treatment.  In  recent  years,  molecular  target  therapy  is  a  new  treatment  
modality  for  gastric  cancer  and  HER2/neu  has  been  identified  as  a  
potential  therapeutic  target.  Over expression  of  HER 2/neu   receptor  in 
gastric  carcinoma  using  immunohistochemistry  is  detected  in  1986  and  
has  been  recognised  as an  important  prognostic  factor
164
.  
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The  survival  time  of  patients  with   breast  carcinoma  and  positive  
HER2/neu  disease  is  significantly  shorter  than  that  those  with  
HER2/neu  negative  tumour.
165,166
Thus  detection  of  HER2/neu  status  is  
of  greater  significance  in  diagnosis  of  gastric  carcinoma.   
The  pressing  clinical  question   is  whether  or  not  HER2/neu  
expression   confers  prognostic  information.  Over expression  of  
HER2/neu  in  gastric  cancer  varies  from  8.2%  to  62.5%  in  different  
reports.
167
  Some  studies  revealed  HER2/neu   appears  to  be  a  valuable  
prognostic  factor.
16,168
 However ,  the  clinical  significance  of  this  finding  
yet  to  be  clearly  defined. In  literature, few  studies  have  shown  a strong  
association  between  HER2/neu  over expression  and  worse  prognosis.
169 
Due  to  genetic  heterogeneity   of  gastric  carcinoma, the  HER2/neu  
over expression  and   amplification  are   different  when  compared  to  
breast  carcinoma.  This  variation  may  be  explained  by  different  sample  
size,  and  also  other  possible  reasons  for  this  wide  variation  includes  
pre  analytical  variables, such  as  differences  in  fixation  technique, 
antibodies , scoring  system, staining  methods,   subjectivity  of  pathologist  
interpretation  and  intra  tumoural  staining  heterogeneity.  Studies   are  
needed  for  evaluating  the  validity  of  commercially  available  antibodies. 
  
103 
 
 
 
In  this  study,  over  expression  of  HER2/neu protein  observed  in  8 
of  50  gastric  carcinoma  specimens  as  determined  by  IHC.  According  
to  this  findings,  16%  of  patients  expressed  HER2/neu  protein  by  IHC.  
In  this  study,  we  have  found  a  statistically  significant  association  
between  positivity  for  HER2/neu  and  tumour  location.  It  shows  
correlation  with  higher  rate  of  HER2/neu  positivity  in  OGJ & corpus  
cancer  than   antral-pylorus cancer (35.29%  Vs  6.06%  respectively ) with  
a  p value  <0.05,  and  it  is  consistent  with  results  of  other  studies.   
M.Tanner et al (2005)
170
  found  that  positive  rates  of  HER2/neu   ranges  
from 24% to 12%  for  tumours  located  at  the  gastro  oesophageal  
junction  or  in  other areas  of  the  stomach,  respectively.  The 2009 TOGA  
(Trastuzumab for Gastric Cancer) trial also  revealed  in  the  same  way  and  
showed  a  positivity  which  ranges   between 32% and18%,  respectively.
171
 
In  contrast,  Marx Andreas H., et al (2009)  found  that  there  was  no  
statistically  significant  difference   between  HER2/neu  positivity  and  
tumour  site.
172
 
In  these  we   have  also  found  statistically  significant  association  
between  signet  ring  cell  carcinoma  and  HER2/neu  expression (40%),   
with  p value of  <0.05.  Conflicting  evidence regarding HER2 and signet 
ring cell features exists.    
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Cangiano J et al (2008)
173
 study  found  that   tumours  showing  signet  ring  
cell  features  uniformly  overexpressed  HER2/neu  as  measured  by  IHC, 
although the sample  size  was  not  reported and  determination of  HER2  
protein  status  relied  on   the  breast  cancer  scoring  system  for  IHC  
without molecular  analysis (FISH). Future studies should make an effort to 
quantify the association between signet ring carcinoma  and HER2/neu 
status.  
In  contrast,  Grabsch  H et al (2010)
167
 reported  that  there  is  no  
significant  correlation  between  signet  cell  features and  HER2/neu  
expression. 
In  this  study  there  was  no significant  correlation    between  
HER2neu expression  and  the  clinicopathologic  prognostic  factors ,  such  
as  age, gender, similar  to  the  studies  done  by  M.Tanner  et al 
(2005)
170
,AnanievJulian, et al (2011).
174
 
In  this  study,  no  relationship  was  found  between  HER2neu  
expression  and  primary  tumour  size, TNM staging, nodal  status, lymph  
node  ratio and  it  is  consistent  with  of  other  studies. Ghaderi, Abbas, et 
al(2002) reported  that   HER2 neu  overexpression  was  not  associated  
with tumour stage
175
 
Halon Agnieszka, et al (2012) observed  that  there  was  no 
relationship  found  between  HER2neu  and  primary tumour  size and  
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degree  of  spread  to  regional  lymph  nodes.
176
 HER2neu  expression  was  
evaluated  by immunohistochemical  method  and  the  results  were  similar  
to  our  study.  
In contrast, Wang Yuan-Yu, et al (2011) Positive  expression of   
HER2neu  correlated  with age, size of tumour, location of tumour, depth of 
invasion, vessel invasion, lymph node, and distant metastasis and TNM 
stage
177 
GZ Yu et al (2009)  also  observed  significant  differences in 
HER2neu expression between the primary tumours and the lymph node 
metastases (P < 0.01). Overexpression ofHer2 was associated with age (>60 
years), tumour location (cardia of stomach), adenocarcinoma, and 
high/moderate differentiation
184. 
We  did  not  observe  a  statistically  significant  correlation  between  
HER2/neu  overexpression and  Lauren’s  classification ,  which  has a 
prognostic  significance.  C. Gravalos  and  A. Jimeno (2008), reported the  
relationship  between  HER-2/neu  overexpression  and  Lauren’s 
classification  of  tumours
178
.  But  this  correlation  was  not  statistically 
significant. Y Kang et al (2008)reported  that  HER-2/neu overexpression  
correlated  with  the  histological  type  as in Lauren’s classification  with  
34% intestinal type; 6% diffuse being  HER2/neu positive
179
. 
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Due  to  significant  differences  in  the  historical  studies, the role of  
HER2/neu as a prognostic marker  in gastric carcinoma  has been 
controversial.  More recent studies found  that HER2/neu  is an important  
poor prognostic  factor  in  gastric  cancer patients.
180-183
 This  study  
concludes that  HER2/neu status  has  a  significant  role  in  prognosis of  
gastric carcinoma  and  may  be  considered  as  an  independent  prognostic  
factor  in  gastric carcinoma  patients.  So  further  study  is  needed  to  
explain  the  role of  HER2/neu on  development  and prognosis of gastric 
cancer. 
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SUMMARY 
1. HER2 neu  expression  in  Gastric  adenocarcinoma  is  16%. 
2. Her2 neu  expression  is  more  in  Oesophageal  gastric  junctional  & 
corpus  location  of  tumours (35.3%) compared to Pylorus-Antral  
tumours. 
3. Her2 neu  expression  is  more  in  patients  with  signet  ring  cell 
carcinoma  (40%)  compared  to  Non signet  ring  cell  carcinoma. 
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CONCLUSION 
1. HER2neu  expression  in  Gastric  cancer  has  a  role  to  play  as  an  
independent  prognostic  factor  and    requires  additional  studies.  
2. This  study  concludes  that  the  Histological  type  of  signet  ring  
cell  carcinoma, act  as  a as  an  independent  prognostic  factor. 
3. Tumour  located  in  Oesophageal  gastric   junction & corpus of  the  
stomach  is  the  candidate   parameter   for  prognostication.  
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GASTRIC ADENOCARCINOMA – INTESTINAL TYPE 
 
 
 
 
 
 
 
Figure 31:IT – well differentiated with well             Figure 32: Malignant epithelial cells in  
sheets formed  glands (100X) HPE- 3254/13            with nuclear pleomorphism and   
              prominent   nucleoli (400X) HPE- 3254/13 
 
 
 
 
GASTRIC ADENOCARCINOMA – DIFFUSE  TYPE 
 
 
 
 
 
 
 
 
Figure 33: Poorly cohesive cells diffusely                           Figure 34 : Pleomorphic and  round poorly 
infiltrating the gastric wall. (100X)                                     cohesive cells (400X) HPE- 1992/14                    
HPE-1992/14 
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TUBULAR ADENOCARCINOMA 
 
 
 
 
 
 
Figure 35 : Numerous  tubules  of  varying                 Figure 36 : Tubules lined by cuboidal to 
 Size (100 X) HPE-  108/ 14                                            columnar cells with cytological atypia (400 X)                                                                               
                                                                                          HPE-108 /14 
 
 
 
PAPILLARY ADENOCARCINOMA 
 
 
 
 
 
 
 
Figure 37 : Tumour cells in papillary                                 Figure 38 : Cells in delicate papillary 
pattern with infiltration (100X) HPE- 3469/13                  pattern with fibro – vascular core (400X)  
                                                                                                HPE – 3469/13 
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MUCINOUS ADENOCARCINOMA 
 
 
 
 
 
 
Figure 39  : Chains and clusters of malignant              Figure 40 : Malignant epithelial cells with 
cells  floating in extra – cellular mucin pool                       pleomorphism and scattered signet ring cells 
(100X) HPE – 1933/13                                                       (400X) HPE – 1933/13 
 
 
SIGNET RING ADENOCARCINOMA 
 
 
 
 
 
 
Figure 41 : Sheets of signet ring cells forming          Figure 42 : Sheets of malignant cells with 
>50% of the tumour. (100X) HPE – 3129/13             abundant intra-cytoplasmic mucin.  
         (400X) HPE – 3129/13 
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OTHER PROGNOSTIC FACTORS 
 
  
 
 
 
 
Figure 43 : Vascular invasion (400X)                        Figure 44 : Lymphatic  invasion (400X) 
HPE – 3129/13                                                             HPE - 2704/12 
 
 
 
 
 
 
 
 
 
 
Figure 45 : Perineural infiltration (100X)                  Figure 46 : Metastatic deposit in node 
HPE – 1069/14 (100X)                                                  HPE – 2271/13 
 
 
  
 
 
 
 
 
 
 
 
 
Figure 47: Membranous  HER2/neu  3+ posi
HPE-2398/12   
 
 
 
 
 
 
 
 
 
 
 
 
5 
HER2/neu  EXPRESSION 
 
tivity     Figure 48 : HER2 neu  membranous
                  positivity (3+) HPE-
 
1195/14    
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 ANNEXURE – I 
                                                 PROFORMA 
 
Case number                        :                                              Name : 
HPE number                        :                                              Age : 
IP number                            :                                             Gender : 
Clinical history : 
Risk factors, if any : 
Clinical diagnosis : 
Imaging : 
Endoscopy : 
Previous HPE report: 
Nature of  specimen :     Total gastrectomy/Subtotal gastrectomy/Others 
GROSS 
Proximal circumference :                                         Greater curvature: 
Distal circumference :                                               Lesser curvature : 
Tumour site : 
Tumour size : 
Tumour configuration:                                               Depth of invasion: 
Margins:                           Proximal :                         Distal : 
 
Associated findings : 
Total nodes dissected : 
MICROSCOPY 
Histological type : 
Histological grade :  
Depth of invasion : 
Margins :                       Proximal :       Free / Involved 
                                       Distal      :       Free / Involved 
 
Lymphatic invasion     : Present / Absent 
Venous invasion          : Present / Absent 
Perineural invasion      : Present / Absent 
Associated findings: 
Total number of nodes dissected: Number of nodes involved: 
Distant metastasis : 
TNM staging : 
IMMUNOHISTOCHEMISTRY 
HER2neu  score : 
 ANNEXURE II 
HAEMATOXYLIN & EOSIN STAINING TECHNIQUE
[90] 
PREPARATION OF HAEMATOXYLIN SOLUTION: 
Haematoxylin                                                   2. 5gm 
Mercuric oxide                                                 1.25gm 
Potassium alum                                                 50gm 
Absolute ethyl alcohol                                      25ml 
Sodium iodate                                                   0.5gm      
Distilled water                                                  500ml 
PROCEDURE: 
                      Potassium alum, 50gm is dissolved in 500ml of distilled water by 
heating and shaking at 60
0
 C. Add solution of 2.5gm of Haematoxylin in 25ml of 
absolute ethyl alcohol and bring rapidly to boil. When it begins to boil, remove 
from flame and add 1.25gm of mercuric oxide or sodium iodate. Mix by swirling 
gently. 
PREPARATION OF EOSIN SOLUTION: 
Eosin Y                                                              1gm 
95% Ethanol                                                      80ml 
Glacial Acetic acid                                            0.2ml 
Distilled water        20ml 
PROCEDURE: 
           Dissolve 1gm Eosin Y in 20ml of distilled water and add 80ml of 95% 
etanol and 0.2ml of glacial acetic acid. 
STAINING PROCEDURE: 
1.Xylene 3 changes-2mins each. 
2.90%, 80%, 70% alcohol-10 dips each. 
3. Bring sections to water. 
4. Harris Haematoxylin-15 minutes. 
5. Rinse in tap water. 
6. Differentiate in 1% acid alcohol. 
7. Rinse in tap water. 
8. Lithium carbonate 0.5%- until blue. 
9. Tap water wash. 
 
 
 
 
 
 
ANNEXURE III 
TNM STAGING OF GASTRIC TUMOURS 
T – Primary Tumour 
TX - Primary tumour cannot be assessed 
T0 - No evidence of primary tumour 
Tis - Carcinoma in situ 
T1 - Tumour invades lamina propria or submucosa 
T2 - Tumour invades muscularispropria 
T3 - Tumour penetrates subserosaconnective tissue without invasion of  
visceral peritoneum or adjacent structures 
T4 - Tumour invades serosa  oradjacent structures 
T4a-Tumour invade serosa 
T4b-Tumour invades adjacent structures 
N – Regional Lymph Nodes 
NX - Regional lymph nodes cannot be assessed 
N0 - No regional lymph node metastasis 
N1 - Metastasis in 1 or 2 positive  lymph nodes 
N2 - Metastasis in  3  to  6  positive  lymph nodes  
N3 - Metastasis in 7 or  morepositive lymph nodes 
 
M – Distant Metastasis 
MX - Distant metastasis cannot be assessed 
M0 - No distant metastasis 
M1 - Distant metastasis, positive peritoneal cytology 
STAGING 
STAGE T N M 
Stage 0 Tis N0 M0 
Stage IA T1 N0 MO 
Stage IB 
T1 
T2 
N1 
N0 
M0 
M0 
Stage IIA 
T1 
T2 
T3 
N3 
N2 
N1 
M0 
M0 
M0 
Stage I I B 
T1 
T2 
T3 
T4a 
N3 
N2 
N1 
N0 
M0 
M0 
M0 
M0 
Stage IIIA 
T2 
T3 
T4a 
N3 
N2 
N1 
M0 
M0 
M0 
Stage IIIB 
T3b 
T4a 
T4b 
N3 
N2 
N0/N1 
M0 
M0 
M0 
Stage IIIC 
T4a 
T4b 
N3 
N2/N3 
M0 
M0 
Stage IV Any T Any N M1 
 
                                         
 
 
ANNEXURE IV 
PROCESSING FOR IMMUNOHISTOCHEMISTRY 
• 3µm  thick  sections  obtained  from  paraffin  embedded  blocks  and  
sections  taken  on  poly L- lysine  coated  adhesive  slides .  The slides are 
incubated at 60º C  for one hour.   
• The slides are subjected to 2 changes of xylene  5  minutes each for 
deparaffinization. 
• They are then transferred to absolute alcohol for 5 minutes followed by by 
80% and 70% alcohol for 5 minutes to rehydrate the tissue sections. 
•  Tissue sections are then placed in running tap water for 5 minutes and 
washed in distilled water 
• Antigen  retrieval was performed using pressure cooker in specific buffer 
(citrate buffer for HER2/neu , Ph 6.0)        
• Then the sections are cooled to room temperature and the slides are washed 
with distilled water. 
• 3% Peroxide  block  was applied for 5 min and washed with a TRIS  wash  
buffer  solution  for  2 × 5 min  to  reduce the nonspecific staining due to  
endogenous peroxidase  activity. 
• Then protein block was applied and incubated for 5 minutes to block 
nonspecific background staining. 
• Rabbit  anti human  polyclonal  Her2/neu  antibody ( thermo  fisher  
scicntific)  is then added over the tissue and incubated for 30 minutes 
• .Followed by the  primary  horse radish  peroxidase  polymer  amplifier  is 
added for 15 minutes to enhance the process of primary antibody which is 
then washed in TRIS  wash buffer. 
• Secondary antibody is added and incubated for 20 minutes  and then washed 
with TRIS  wash buffer. 
• The bound antibody was visualized  using  a diaminobenzidine ( DAB) 
chromogen (1ml DAB buffer +1 drop DAB chromogen)  and incubate for 5 
minutes  and  then washed  with  2  changes  of  distilled water.  
•   Counterstaining  was  done  with  Mayer’s hematoxylin  for  30  seconds  
and  washed  in  tap  water. 
• Dehydration is done by  2 changes of   100 % alcohol. 
• Mounting is done by DPX mountant and observed under microscope. 
BUFFER PREPARATIONS 
1) Tris – EDTA Buffer: - PH- 9.0 
Tris                -  6.05 Gm 
EDTA            -  0.744gms 
Distilled water   -  1000ml 
Section  stained by omission of  the primary antibody  was  used  as  a  
negative  control . Over-expression of HER-2/neu   protein  in paraffin-embedded 
invasive breast carcinoma tissue  slides was used as a positive control. 
 
 
 
 
 
c
a
s
e
IP
 N
O
A
G
E
S
E
X
P
R
O
C
S
IT
E
S
IZ
E
G
R
O
S
S
- 
P
R
M
G
R
O
S
S
-D
R
M
S
I
H
IS
T
.T
Y
P
E
L
A
U
R
E
N
'S
T
  
  
  
  
 N
  
  
  
  
M
S
T
A
G
E
L
I
P
N
I
M
A
R
G
IN
S
R
M
T
L
N
P
N
L
N
R
H
E
R
2
-n
e
u
1
8
/2
0
1
2
1
0
0
5
4
0
M
P
.G
P
Y
LO
R
O
-A
N
T
R
U
M
4
×
4
N
I
I
P
S
IG
N
E
T
D
T
T
3
N
2
M
0
II
I 
A
A
A
D
IS
T
A
L
R
2
4
3
0
.7
5
0
4
1
8
/1
2
3
6
6
8
6
6
M
P
.G
B
O
D
Y
4
×
2
N
I
N
I
P
P
A
P
IL
LA
R
Y
IT
T
3
N
0
M
0
II
 A
P
P
F
R
E
E
R
0
5
0
0
1
+
4
6
8
/1
2
5
1
8
3
4
0
M
P
.G
P
Y
LO
R
O
-A
N
T
R
U
M
2
×
2
N
I
N
I
P
T
U
B
U
LA
R
IT
T
3
N
3
M
0
II
IB
A
A
F
R
E
E
R
0
7
7
1
1
+
7
6
1
/1
2
1
3
9
4
7
3
7
F
T
.G
B
O
D
Y
1
0
×
5
I
I
P
D
IF
F
U
S
E
D
T
T
3
N
1
M
0
II
B
A
A
B
O
T
H
R
2
1
2
2
0
.1
7
0
8
8
3
/1
2
1
8
1
4
3
5
0
M
T
.G
B
O
D
Y
7
×
5
N
I
I
A
T
U
B
U
LA
R
IT
T
2
N
2
M
0
II
B
P
A
D
IS
T
A
L
R
2
4
3
0
.7
5
2
+
1
0
4
1
/1
2
1
9
9
4
7
6
2
M
P
.G
P
Y
LO
R
O
-A
N
T
R
U
M
5
.5
×
1
.5
N
I
N
I
P
S
IG
N
E
T
D
T
T
3
N
0
M
0
II
A
P
A
F
R
E
E
R
0
1
0
0
1
+
1
1
7
1
/1
2
2
2
9
2
0
4
2
M
P
.G
P
Y
LO
R
O
-A
N
T
R
U
M
3
×
2
N
I
+
P
T
U
B
U
LA
R
IT
T
3
N
1
M
0
II
B
A
A
D
IS
T
A
L
R
2
4
2
0
.5
0
1
2
1
8
/1
2
2
5
4
4
2
6
0
F
P
.G
P
Y
LO
R
O
-A
N
T
R
U
M
3
×
2
N
I
N
I
P
T
U
B
U
LA
R
IT
T
3
N
2
M
0
II
I 
A
P
A
F
R
E
E
R
0
6
6
1
1
+
1
4
9
7
/1
2
3
2
3
5
3
4
5
F
P
.G
P
Y
LO
R
O
-A
N
T
R
U
M
5
×
3
N
I
N
I
P
D
IF
F
U
S
E
D
T
T
3
N
2
M
0
II
I 
A
P
P
F
R
E
E
R
0
5
3
0
.6
0
1
8
2
5
/1
2
3
7
6
7
7
5
7
M
P
.G
P
Y
LO
R
O
-A
N
T
R
U
M
5
×
4
N
I
I
P
D
IF
F
U
S
E
D
T
T
3
N
0
M
0
II
A
A
A
D
IS
T
A
L
R
2
0
0
0
0
2
0
2
7
/1
2
4
3
7
2
8
5
7
M
P
.G
P
Y
LO
R
U
S
4
×
4
N
I
N
I
A
P
A
P
IL
LA
R
Y
IT
T
2
N
2
M
0
II
B
A
A
F
R
E
E
R
0
4
3
0
.7
5
1
+
2
2
6
0
/1
2
4
5
4
9
5
6
5
F
P
.G
B
O
D
Y
4
×
3
N
I
I
A
D
IF
F
U
S
E
D
T
T
3
N
0
M
0
II
A
P
A
D
IS
T
A
L
R
2
6
0
0
0
2
2
8
9
/1
2
4
8
5
0
9
6
0
M
P
.G
P
Y
LO
R
U
S
7
.5
×
4
N
I
I
P
S
IG
N
E
T
D
T
T
3
N
1
M
0
II
B
A
A
D
IS
T
A
L
R
2
6
2
0
.3
3
3
0
2
3
0
0
/1
2
4
9
8
9
9
4
0
M
P
.G
P
Y
LO
R
U
S
5
×
4
N
I
I
P
T
U
B
U
LA
R
IT
T
3
N
2
M
0
II
I 
A
P
P
D
IS
T
A
L
R
2
9
3
0
.3
3
3
1
+
2
3
9
7
/1
2
4
7
0
9
9
4
5
M
P
.G
P
Y
LO
R
U
S
7
.5
×
4
N
I
I
A
S
IG
N
E
T
D
T
T
2
N
3
M
0
II
I 
A
P
A
D
IS
T
A
L
R
2
1
2
9
0
.7
5
1
+
2
3
9
8
/1
2
4
8
7
9
9
5
1
M
P
.G
B
O
D
Y
2
×
1
I
N
I
A
P
A
P
IL
LA
R
Y
IT
T
3
N
2
M
0
II
I 
A
P
P
B
O
T
H
R
2
8
4
0
.5
3
+
2
4
1
5
/1
2
4
9
4
7
4
4
2
F
P
.G
B
O
D
Y
7
×
5
I
N
I
P
M
U
C
IN
O
U
S
D
T
T
3
N
3
M
0
II
IB
P
P
B
O
T
H
R
2
1
9
1
6
0
.4
5
7
0
2
4
4
7
/1
2
4
9
6
4
0
6
5
M
P
.G
B
O
D
Y
6
×
5
I
N
I
P
S
IG
N
E
T
D
T
T
3
N
2
M
0
II
I 
A
P
P
P
R
O
X
IM
A
L
R
2
3
3
1
2
+
2
7
0
4
/1
2
5
5
4
4
7
4
9
F
P
.G
P
Y
LO
R
O
-A
N
T
R
U
M
3
.5
×
0
.7
N
I
I
A
S
IG
N
E
T
IT
T
3
N
1
M
0
II
B
P
P
D
IS
T
A
L
R
2
1
1
1
0
2
7
2
5
/1
2
5
5
4
6
7
5
8
M
P
.G
P
Y
LO
R
O
-A
N
T
R
U
M
6
×
4
N
I
I
A
D
IF
F
U
S
E
IT
T
3
N
1
M
0
II
B
A
A
D
IS
T
A
L
R
2
4
4
1
0
2
7
6
3
/1
2
5
6
4
4
9
7
0
F
P
.G
P
Y
LO
R
O
-A
N
T
R
U
M
4
×
4
N
I
N
I
A
T
U
B
U
LA
R
IT
T
2
N
0
M
0
IB
A
A
F
R
E
E
R
0
0
0
0
0
2
9
9
5
/1
2
6
2
9
5
6
3
8
F
P
.G
P
Y
LO
R
O
-A
N
T
R
U
M
2
.5
×
2
I
N
I
P
P
A
P
IL
LA
R
Y
IT
T
3
N
1
M
0
II
B
A
A
D
IS
T
A
L
R
2
4
2
0
.5
0
3
0
9
5
/1
2
6
3
2
8
3
6
5
M
P
.G
P
Y
LO
R
IC
 A
N
T
R
U
M
7
×
4
N
I
N
I
P
D
IF
F
U
S
E
D
T
T
3
N
2
M
0
II
IA
A
A
F
R
E
E
R
0
2
1
0
.5
1
+
3
2
2
2
/1
2
6
6
4
8
0
6
5
M
P
.G
B
O
D
Y
3
.5
×
2
N
I
I
P
T
U
B
U
LA
R
IT
T
3
N
2
M
0
II
I 
A
A
A
D
IS
T
A
L
R
2
5
3
0
.6
0
3
2
8
5
/1
2
6
7
3
6
3
6
5
F
P
.G
P
Y
LO
R
O
-A
N
T
R
U
M
4
×
4
N
I
I
P
S
IG
N
E
T
D
T
T
3
N
2
M
0
II
I 
A
A
A
D
IS
T
A
L
R
2
4
4
1
2
+
1
2
8
/1
3
2
4
3
6
6
5
M
T
.G
P
Y
LO
R
O
-A
N
T
R
U
M
4
×
3
N
I
I
A
D
IF
F
U
S
E
D
T
T
2
N
3
M
0
II
I 
A
P
A
F
R
E
E
R
2
1
1
1
1
1
0
2
5
5
/1
3
5
4
5
6
5
5
M
T
.G
P
Y
LO
R
O
-A
N
T
R
U
M
7
×
3
I
N
I
P
T
U
B
U
LA
R
IT
T
3
N
2
M
0
II
I 
A
P
P
F
R
E
E
R
2
6
5
0
.8
3
0
1
9
3
3
/1
3
3
6
4
5
6
7
2
M
P
.G
P
Y
LO
R
O
-A
N
T
R
U
M
6
×
1
.5
N
I
N
I
A
M
U
C
IN
O
U
S
D
T
T
2
N
2
M
0
II
B
P
A
F
R
E
E
R
0
6
3
0
.5
0
2
0
3
5
/1
3
3
8
4
1
6
6
8
M
P
.G
O
G
J
8
×
6
N
I
N
I
A
S
IG
N
E
T
D
T
T
2
N
1
M
0
II
A
P
P
F
R
E
E
R
0
6
2
0
.3
3
3
3
+
2
0
5
8
/1
3
4
4
8
0
0
4
1
F
P
.G
P
Y
LO
R
O
-A
N
T
R
U
M
8
×
4
N
I
N
I
A
T
U
B
U
LA
R
IT
T
2
N
3
M
0
II
I 
A
P
A
F
R
E
E
R
0
5
5
1
1
+
2
2
0
6
/1
3
4
3
5
1
7
6
0
F
P
.G
B
O
D
Y
 
7
×
6
N
I
N
I
A
S
IG
N
E
T
D
T
T
3
N
3
M
0
II
IB
P
P
F
R
E
E
R
0
1
2
1
2
1
2
+
2
2
7
1
/1
3
4
7
5
6
8
6
2
F
P
.G
B
O
D
Y
5
.5
×
3
N
I
N
I
A
T
U
B
U
LA
R
IT
T
3
N
1
M
0
II
B
P
A
F
R
E
E
R
0
4
1
0
.2
5
3
+
2
2
9
4
/1
3
4
9
9
9
4
5
8
M
P
.G
B
O
D
Y
6
×
4
N
I
N
I
A
T
U
B
U
LA
R
IT
T
2
N
O
M
0
IB
P
A
F
R
E
E
R
0
2
0
0
1
+
2
4
3
9
/1
3
5
3
1
0
1
4
5
F
P
.G
P
Y
LO
R
O
-A
N
T
R
U
M
3
×
1
.2
N
I
N
I
A
T
U
B
U
LA
R
IT
T
2
N
0
M
0
IB
P
P
F
R
E
E
R
0
3
0
0
0
2
7
5
6
/1
3
5
5
5
1
0
6
5
F
P
.G
P
Y
LO
R
O
-A
N
T
R
U
M
4
×
1
N
I
N
I
P
T
U
B
U
LA
R
IT
T
3
N
1
M
0
II
B
P
A
F
R
E
E
R
0
2
1
0
.5
1
+
3
1
2
9
/1
3
6
2
4
8
6
6
5
M
P
.G
O
G
J
1
0
×
9
N
I
N
I
A
S
IG
N
E
T
D
T
T
2
N
1
M
0
II
A
A
A
F
R
E
E
R
0
5
1
0
.2
0
3
2
5
4
/1
3
6
3
2
5
0
8
0
F
P
.G
B
O
D
Y
5
×
4
N
I
N
I
P
P
A
P
IL
LA
R
Y
IT
T
3
N
0
M
0
II
A
P
A
F
R
E
E
R
0
3
0
0
0
3
4
6
9
/1
3
7
1
7
9
9
5
5
F
P
.G
B
O
D
Y
5
×
3
N
I
N
I
A
P
A
P
IL
LA
R
Y
IT
T
2
N
O
M
0
IB
P
A
F
R
E
E
R
0
1
1
0
0
1
+
9
5
/1
4
2
3
4
5
4
4
F
P
.G
P
Y
LO
R
O
-A
N
T
R
U
M
4
×
3
.5
N
I
N
I
P
T
U
B
U
LA
R
IT
T
3
N
0
M
0
II
A
P
A
F
R
E
E
R
0
1
1
0
0
0
1
0
8
/1
4
4
5
6
7
7
0
M
P
.G
P
Y
LO
R
O
-A
N
T
R
U
M
3
×
2
.5
N
I
N
I
A
T
U
B
U
LA
R
IT
T
3
N
2
M
0
II
I 
A
A
A
F
R
E
E
R
0
1
0
6
0
.6
0
3
8
4
/1
4
8
2
4
7
4
3
M
T
.G
P
Y
LO
R
O
-A
N
T
R
U
M
5
×
3
N
I
N
I
A
P
A
P
IL
LA
R
Y
IT
T
2
N
2
M
0
II
B
P
P
F
R
E
E
R
0
5
4
0
.8
1
+
7
7
6
/1
4
1
1
8
9
5
6
3
F
P
.G
P
Y
LO
R
O
-A
N
T
R
U
M
4
.5
×
1
.5
N
I
N
I
A
T
U
B
U
LA
R
IT
T
2
N
0
M
0
IB
P
P
F
R
E
E
R
0
2
0
0
1
+
1
0
6
9
/1
4
1
7
9
4
3
6
7
M
T
.G
B
O
D
Y
5
×
2
.5
N
I
N
I
A
T
U
B
U
LA
R
IT
T
3
N
1
M
0
II
B
P
P
F
R
E
E
R
0
3
2
0
.6
6
6
0
1
4
0
6
/1
4
2
4
7
4
3
5
5
M
P
.G
P
Y
LO
R
O
-A
N
T
R
U
M
3
×
1
.5
N
I
N
I
A
T
U
B
U
LA
R
IT
T
2
N
0
M
0
IB
P
A
D
IS
T
A
L
R
1
1
0
0
0
1
4
6
3
/1
4
2
3
7
0
9
4
5
M
P
.G
P
Y
LO
R
IC
 A
N
T
R
U
M
7
×
7
N
I
N
I
A
T
U
B
U
LA
R
IT
T
2
N
3
M
0
II
I 
A
P
A
F
R
E
E
R
0
1
2
1
2
1
1
+
1
5
3
0
/1
4
2
6
3
5
9
5
7
M
P
.G
P
Y
LO
R
O
-A
N
T
R
U
M
4
×
2
.5
N
I
N
I
A
T
U
B
U
LA
R
IT
T
3
N
1
M
0
II
B
P
A
F
R
E
E
R
0
8
2
0
.2
5
1
+
1
1
9
5
/1
4
1
6
7
8
7
6
0
M
P
.G
P
Y
LO
R
O
-A
N
T
R
U
M
3
.5
×
2
N
I
N
I
A
T
U
B
U
LA
R
IT
T
3
N
2
M
0
II
I 
A
P
A
F
R
E
E
R
0
5
5
1
3
+
1
9
9
2
/1
4
3
3
9
2
3
5
7
F
P
.G
P
Y
LO
R
O
-A
N
T
R
U
M
7
.5
×
6
N
I
N
I
P
D
IF
F
U
S
E
D
T
T
4
N
1
M
0
II
IB
P
A
F
R
E
E
R
0
6
1
0
.1
6
6
0
2
3
0
1
/1
4
3
8
3
3
1
5
2
M
P
.G
B
O
D
Y
6
×
4
N
I
N
I
P
T
U
B
U
LA
R
IT
T
3
N
1
M
0
II
B
A
A
F
R
E
E
R
0
6
1
0
.1
6
6
0
2
3
0
0
/1
4
3
8
4
8
1
4
5
M
P
.G
P
Y
LO
R
O
-A
N
T
R
U
M
6
.5
×
5
N
I
N
I
A
T
U
B
U
LA
R
IT
T
3
N
0
M
0
II
A
P
A
F
R
E
E
R
0
0
0
0
0
KEY  TO  MASTER CHART 
Proc   –  Procedure 
Hist.  –  Histological 
LI  – Lymphatic invasion 
VI  –  Vascular invasion 
PNI  –  Perineural invasion 
LN  –  Lymph Node status 
PG  –  Partial Gastrectomy 
TG  –  Total Gastrectomy 
IT  –  Intestinal Type 
DT  –  Diffuse Type 
G  –  Grade 
T  –  Tumour depth 
P  – Present 
A  –  Absent 
N  – Node 
M – Metastasis 
NI – Not Involved 
I – Involved 
RM – Resected Margins 
TLN – Total Lymph Nodes 
PN – Positive Nodes 
LNR – Lymph Node Ratio 
